


**CUMULATIVE
SUPPLEMENT 05
May 2009**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

29th EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2009

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

29th EDITION

Cumulative Supplement 5

May 2009

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Availability of the Edition	v
1.5 Report of Counts for the Prescription Drug Product List	vi
1.6 Cumulative Supplement Legend	vii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

29th EDITION

**CUMULATIVE SUPPLEMENT 5
May 2009**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 28th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 29th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 30th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@cder.fda.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7500 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
DABUR ONCOLOGY PLC (DABUR ONCOLOGY PLC)	FRESENIUS KABI ONCOLOGY PLC (FRESENIUS KABI ONCOL)
TORPHARM INC (TORPHARM)	APOTEX INC (APOTEX)

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Annual Edition. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.exe and eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly. Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2008</u>	<u>MAR 2009</u>	<u>JUN 2009</u>	<u>SEPT 2009</u>
DRUG PRODUCTS LISTED	12751	12910		
SINGLE SOURCE	2433	2449		
	(19.1%)	(19.0%)		
MULTISOURCE	10229	10372		
	(80.2%)	(80.3%)		
THERAPEUTICALLY EQUIVALENT	10072	10216		
	(79.0%)	(79.1%)		
NOT THERAPEUTICALLY EQUIVALENT ¹	157	156		
EXCEPTIONS ¹	(1.2%)	(1.2%)		
	89	89		
	(0.7%)	(0.7%)		
NEW MOLECULAR ENTITIES				
APPROVED	15	5		
NUMBER OF APPLICANTS	719	724		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name

	and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 28TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

1-1

ACARBOSE

TABLET; ORAL

ACARBOSE

>A>	AB	IMPAX LABS	25MG	N78441 001	May 14, 2009	May	NEWA
>A>	AB		50MG	N78441 002	May 14, 2009	May	NEWA
>A>	AB		100MG	N78441 003	May 14, 2009	May	NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ SANDOZ 300MG;30MG

N81250 001 Jul 16, 1992 Mar DISC

@ 300MG;60MG

N81249 001 Jul 16, 1992 Mar DISC

TYLENOL W/ CODEINE NO. 4

AA ORTHO MCNEIL JANSSEN 300MG;60MG

N85055 004 Mar CMFD

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ MALLINCKRODT 500MG;5MG

N89006 001 Aug 09, 1985 Feb CTNA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

PERCOCET

>D> + ENDO PHARMS 325MG;2.5MG

N40330 001 Jun 25, 1999 May CTEC

>A> AA + 325MG;2.5MG

N40330 001 Jun 25, 1999 May CTEC

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

@ SANDOZ 650MG;65MG

N89959 001 Jul 18, 1989 Mar DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

@ SANDOZ 650MG;100MG

N70443 001 Jan 23, 1986 Mar DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB MYLAN 325MG;37.5MG

N77858 001 Sep 26, 2008 Apr CAHN

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

@ HOSPIRA EQ 500MG BASE/VIAL

N40108 001 Oct 30, 1995 Apr DISC

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

@ HOSPIRA EQ 500MG BASE/VIAL

N74758 001 Apr 22, 1997 Apr DISC

@ EQ 1GM BASE/VIAL

N74758 002 Apr 22, 1997 Apr DISC

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

AP	LUITPOLD	3MG/ML	N90010 001	Apr 28, 2009	Apr	NEWA
>A> AP	STRIDES ARCOLAB LTD	3MG/ML	N78686 001	May 13, 2009	May	NEWA

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

@ ARMSTRONG PHARMS	0.09MG/INH	N72273 001	Aug 14, 1996	Jan	DISC
--------------------	------------	------------	--------------	-----	------

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

@ BAUSCH AND LOMB	EQ 0.083% BASE	N75358 001	Mar 29, 2000	Apr	DISC
AN HOLOPACK INTL	EQ 0.083% BASE	N77839 001	Dec 16, 2008	Jan	CAHN
AN TEVA PARENTERAL	EQ 0.083% BASE	N75343 001	Nov 09, 1999	Apr	CAHN

TABLET; ORAL

ALBUTEROL SULFATE

@ SANDOZ	EQ 2MG BASE	N72151 001	Dec 05, 1989	Mar	DISC
@	EQ 4MG BASE	N72152 001	Dec 05, 1989	Mar	DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN TEVA PARENTERAL	EQ 0.083% BASE;0.017%	N76724 001	Dec 31, 2007	Apr	CAHN
--------------------	-----------------------	------------	--------------	-----	------

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB SANDOZ	EQ 5MG BASE	N75871 001	Apr 22, 2009	Apr	NEWA
AB	EQ 10MG BASE	N75871 002	Apr 22, 2009	Apr	NEWA
AB	EQ 35MG BASE	N75871 004	Apr 22, 2009	Apr	NEWA
AB	EQ 40MG BASE	N75871 003	Apr 22, 2009	Apr	NEWA
AB	EQ 70MG BASE	N75871 005	Apr 22, 2009	Apr	NEWA

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

@ SANDOZ	100MG	N70268 001	Dec 31, 1985	Mar	DISC
@	300MG	N70269 001	Dec 31, 1985	Mar	DISC

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

AB + PAR PHARM	5MG	N70346 001	Jan 22, 1986	Jan	CTEC
AB SIGMAPHARM LABS LLC	5MG	N79133 001	Jan 30, 2009	Jan	NEWA
MIDAMOR					
>D> @ PADDOCK LABS	5MG	N18200 001		May	CMFD
>A> AB	5MG	N18200 001		May	CMFD

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ SANDOZ	EQ 5MG ANHYDROUS;50MG	N73357 001	Nov 27, 1991	Mar	DISC
----------	-----------------------	------------	--------------	-----	------

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

@ HOSPIRA 250MG/ML

N70888 001 Jun 16, 1988 Apr DISC

TABLET; ORAL

AMICAR

XANODYNE PHARM 1GM

N15197 002 Jun 24, 2004 Jan NEWA

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

@ HOSPIRA 100MG/100ML

N88147 002 May 03, 1983 Apr DISC

@ 200MG/100ML

N88147 003 May 03, 1983 Apr DISC

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB MYLAN 200MG

N75188 001 Feb 24, 1999 Apr CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB ALKEM EQ 2.5MG BASE

N78925 001 May 04, 2009 Apr NEWA

AB EQ 5MG BASE

N78925 002 May 04, 2009 Apr NEWA

AB EQ 10MG BASE

N78925 003 May 04, 2009 Apr NEWA

AB GLENMARK GENERICS EQ 2.5MG BASE

N78552 001 Apr 08, 2009 Mar NEWA

AB EQ 5MG BASE

N78552 002 Apr 08, 2009 Mar NEWA

AB EQ 10MG BASE

N78552 003 Apr 08, 2009 Mar NEWA

AB SYNTHON PHARMS EQ 2.5MG BASE

N77080 001 Jun 27, 2007 Jan CAHN

AB EQ 5MG BASE

N77080 002 Jun 27, 2007 Jan CAHN

AB EQ 10MG BASE

N77080 003 Jun 27, 2007 Jan CAHN

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

EXFORGE HCT

NOVARTIS

5MG;12.5MG;160MG

N22314 001 Apr 30, 2009 Apr NEWA

5MG;25MG;160MG

N22314 002 Apr 30, 2009 Apr NEWA

10MG;12.5MG;160MG

N22314 003 Apr 30, 2009 Apr NEWA

+ 10MG;25MG;320MG

N22314 005 Apr 30, 2009 Apr NEWA

10MG;25MG;160MG

N22314 004 Apr 30, 2009 Apr NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB APOTEX 250MG;EQ 125MG BASE

N65333 001 Feb 24, 2009 Feb NEWA

AB 500MG;EQ 125MG BASE

N65333 002 Feb 24, 2009 Feb NEWA

APRACLOINIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

APRACLOINIDINE HYDROCHLORIDE

AT AKORN INC EQ 0.5% BASE

N77764 001 Mar 12, 2009 Feb NEWA

IOPIDINE

AT + ALCON EQ 0.5% BASE

N20258 001 Jul 30, 1993 Feb CFTG

ARMODAFINIL

TABLET; ORAL

NUVIGIL

CEPHALON

100MG

N21875 002 Mar 26, 2009 Mar CMFD

200MG

N21875 005 Mar 26, 2009 Mar NEWA

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

NOVARTIS

20MG;120MG

N22268 001 Apr 07, 2009 Apr NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@ SANDOZ

325MG;50MG;40MG

N86398 002 Apr 06, 1984 Mar DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

@ SOLCO HLTHCARE

385MG;30MG;25MG

N75141 001 May 29, 1998 Jan CAHN

ORPHENGESIC FORTE

@ SOLCO HLTHCARE

770MG;60MG;50MG

N75141 002 May 29, 1998 Jan CAHN

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

@ HOSPIRA

10MG/ML

N74740 001 Mar 28, 1997 Jan DISC

ATRACURIUM BESYLATE PRESERVATIVE FREE

@ HOSPIRA

10MG/ML

N74741 001 Mar 28, 1997 Jan DISC

AZACITIDINE

INJECTABLE; IV-SC

VIDAZA

+ CELGENE

100MG/VIAL

N50794 001 May 19, 2004 Mar CAHN

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

@ APOTEX INC

EQ 0.125MG BASE/SPRAY

N77954 001 Apr 30, 2009 Apr DISC

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

AP SAGENT STRIDES

EQ 500MG BASE/VIAL

N65506 001 Mar 24, 2009 Mar NEWA

BACLOFEN

TABLET; ORAL

BACLOFEN

AB MYLAN

10MG

N77181 001 Jul 29, 2005 Apr CAHN

AB

20MG

N77121 002 Jul 29, 2005 Apr CAHN

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

TREANDA

>A>	+ CEPHALON	25MG/VIAL	N22249 002	May 01, 2009	May	NEWA
-----	------------	-----------	------------	--------------	-----	------

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

COGENTIN

+ LUNDBECK INC	1MG/ML	N12015 001		Apr	CAHN
----------------	--------	------------	--	-----	------

BENZYL ALCOHOL

LOTION; TOPICAL

>D>	BENZYL ALCOHOL					
>D>	+ SCIELE PHARMA INC	5%	N22129 001	Apr 09, 2009	May	CTNA
	+	5%	N22129 001	Apr 09, 2009	Apr	NEWA
>A>	ULESFIA					
>A>	+ SCIELE PHARMA INC	5%	N22129 001	Apr 09, 2009	May	CTNA

BESIFLOXACIN HYDROCHLORIDE

>A>	SUSPENSION/DROPS; OPHTHALMIC					
>A>	BESIVANCE					
>A>	+ BAUSCH AND LOMB	EQ 0.6% BASE	N22308 001	May 28, 2009	May	NEWA

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

TACLONEX

+ LEO PHARM	0.064%;0.005%	N21852 001	Jan 09, 2006	Mar	CAHN
-------------	---------------	------------	--------------	-----	------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

LUXIQ

>A>	+ CONNECTICS	EQ 0.12% BASE	N20934 001	Feb 28, 1999	May	CAHN
>D>	+ STIEFEL LABS INC	EQ 0.12% BASE	N20934 001	Feb 28, 1999	May	CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	SUN PHARM INDS INC	5MG	N40897 001	Apr 22, 2009	Apr	NEWA
AA		10MG	N40897 002	Apr 22, 2009	Apr	NEWA
AA		25MG	N40897 003	Apr 22, 2009	Apr	NEWA
AA		50MG	N40897 004	Apr 22, 2009	Apr	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

AT	TEVA PARENTERAL	0.2%	N76372 001	Sep 10, 2004	Apr	CAHN
----	-----------------	------	------------	--------------	-----	------

BROMOCRIPTINE MESYLATE

TABLET; ORAL

CYCLOSET

>A>	+ VEROSCIENCE	EQ 0.8MG BASE	N20866 001	May 05, 2009	May	NEWA
-----	---------------	---------------	------------	--------------	-----	------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

AA	WOCKHARDT EU	2MG/5ML; 10MG/5ML; 30MG/5ML	N89681 001	Dec 22, 1988	Apr	CAHN
----	--------------	-----------------------------	------------	--------------	-----	------

BUDESONIDE

SUSPENSION; INHALATION

BUDESONIDE

AN	APOTEX	0.25MG/2ML	N78202 001	Mar 30, 2009	Mar	NEWA
AN		0.5MG/2ML	N78202 002	Mar 30, 2009	Mar	NEWA
AN	TEVA PARENTERAL	0.25MG/2ML	N77519 001	Nov 18, 2008	Apr	CAHN
AN		0.5MG/2ML	N77519 002	Nov 18, 2008	Apr	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1	WATSON LABS	100MG	N79095 001	Mar 24, 2009	Mar	NEWA
AB2		150MG	N79094 001	Mar 24, 2009	Mar	NEWA
AB1		150MG	N79095 002	Mar 24, 2009	Mar	NEWA
AB1		200MG	N79095 003	Mar 24, 2009	Mar	NEWA

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

AB	+ BRISTOL MYERS SQUIBB	15MG	N18731 003	Apr 22, 1996	Feb	CRLD
	@	30MG	N18731 004	Apr 22, 1996	Feb	DISC

BUSPIRONE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	5MG	N78246 001	Feb 27, 2009	Feb	NEWA
AB		10MG	N78246 002	Feb 27, 2009	Feb	NEWA
AB		15MG	N78246 003	Feb 27, 2009	Feb	NEWA
AB		30MG	N78246 004	Feb 27, 2009	Feb	NEWA
AB	MYLAN	5MG	N75467 001	Feb 28, 2002	Apr	CAHN
AB		7.5MG	N75467 002	Mar 28, 2001	Apr	CAHN
AB		10MG	N75467 003	Feb 28, 2002	Apr	CAHN
AB		15MG	N75467 004	Feb 28, 2002	Apr	CAHN
	@ SANDOZ	5MG	N75413 001	Mar 19, 2002	Mar	DISC
	@	10MG	N75413 002	Mar 19, 2002	Mar	DISC
	@	15MG	N75413 003	Mar 19, 2002	Mar	DISC

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

AP	HIKMA FARMACEUTICA	1MG/ML	N78400 001	May 01, 2009	Apr	NEWA
AP		2MG/ML	N78247 001	Apr 29, 2009	Apr	NEWA
AP		2MG/ML	N78400 002	May 01, 2009	Apr	NEWA

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFFEINE CITRATE

AP	PADDOCK LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N77233 001	Sep 21, 2006	Apr	CAHN
----	--------------	------------------------------------	------------	--------------	-----	------

CALCITONIN, SALMON

SPRAY, METERED; NASAL

CALCITONIN-SALMON

>A>	AB	MDRNA	200 IU/SPRAY	N76979 001	Jun 08, 2009	May	NEWA
-----	----	-------	--------------	------------	--------------	-----	------

CALCITRIOL

CAPSULE; ORAL

ROCALTROL

AB		VALIDUS PHARMS	0.25UGM	N18044 001		Mar	CAHN
----	--	----------------	---------	------------	--	-----	------

AB	+		0.5UGM	N18044 002		Mar	CAHN
----	---	--	--------	------------	--	-----	------

OINTMENT; TOPICAL

VECTICAL

	+	GALDERMA LABS LP	3UGM/GM	N22087 001	Jan 23, 2009	Jan	NEWA
--	---	------------------	---------	------------	--------------	-----	------

SOLUTION; ORAL

ROCALTROL

AA	+	VALIDUS PHARMS	1UGM/ML	N21068 001	Nov 20, 1998	Mar	CAHN
----	---	----------------	---------	------------	--------------	-----	------

CARBAMAZEPINE

TABLET; ORAL

CARBAMAZEPINE

TORRENT PHARMS

			100MG	N77272 001	Dec 07, 2005	Apr	CAHN
--	--	--	-------	------------	--------------	-----	------

AB			200MG	N77272 002	Dec 07, 2005	Apr	CAHN
----	--	--	-------	------------	--------------	-----	------

			300MG	N77272 003	Dec 07, 2005	Apr	CAHN
--	--	--	-------	------------	--------------	-----	------

			400MG	N77272 004	Dec 07, 2005	Apr	CAHN
--	--	--	-------	------------	--------------	-----	------

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

TORRENT PHARMS

AB			100MG	N75712 001	Jul 05, 2001	Jan	CAHN
----	--	--	-------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

TARO

AB			100MG	N78115 001	Mar 31, 2009	Mar	NEWA
----	--	--	-------	------------	--------------	-----	------

AB			200MG	N78115 002	Mar 31, 2009	Mar	NEWA
----	--	--	-------	------------	--------------	-----	------

AB			400MG	N78115 003	Mar 31, 2009	Mar	NEWA
----	--	--	-------	------------	--------------	-----	------

TEGRETOL-XR

NOVARTIS

AB			100MG	N20234 001	Mar 25, 1996	Mar	CFTG
----	--	--	-------	------------	--------------	-----	------

AB			200MG	N20234 002	Mar 25, 1996	Mar	CFTG
----	--	--	-------	------------	--------------	-----	------

AB	+		400MG	N20234 003	Mar 25, 1996	Mar	CFTG
----	---	--	-------	------------	--------------	-----	------

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

GEOCILLIN

@ PFIZER

EQ 382MG BASE

N50435 001		Mar	DISC
------------	--	-----	------

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

@ SANDOZ

10MG;100MG

N73586 001	Jun 29, 1995	Mar	DISC
------------	--------------	-----	------

@

25MG;100MG

N73587 001	Jun 29, 1995	Mar	DISC
------------	--------------	-----	------

@

25MG;250MG

N73620 001	Jun 29, 1995	Mar	DISC
------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

@ KV PHARM

50MG;200MG

N76663 001	Jun 24, 2004	Apr	DISC
------------	--------------	-----	------

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP	+	WATSON LABS	50MG/VIAL	N76162 001	Oct 14, 2004	Apr	CAHN
AP	+		150MG/VIAL	N76162 002	Oct 14, 2004	Apr	CAHN
AP	+		450MG/VIAL	N76162 003	Oct 14, 2004	Apr	CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP		PHARMACHEMIE BV	EQ 50MG/5ML (10MG/ML)	N77679 001	Feb 25, 2009	Feb	NEWA
AP			EQ 450MG/45ML (10MG/ML)	N77679 003	Feb 25, 2009	Feb	NEWA
AP			EQ 150MG/15ML (10MG/ML)	N77679 002	Feb 25, 2009	Feb	NEWA

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

	@	SANDOZ	350MG	N81025 001	Apr 13, 1989	Mar	DISC
--	---	--------	-------	------------	--------------	-----	------

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP		CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	N65280 001	Mar 18, 2009	Mar	NEWA
AP			EQ 1GM BASE/VIAL	N65280 002	Mar 18, 2009	Mar	NEWA
AP			EQ 10GM BASE/VIAL	N65295 001	Mar 18, 2009	Mar	NEWA
AP			EQ 20GM BASE/VIAL	N65296 001	Mar 18, 2009	Mar	NEWA
	@	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N64033 001	Oct 31, 1993	Mar	DISC

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

AP	+	SANDOZ	EQ 2GM BASE/VIAL	N65169 004	May 09, 2005	Mar	CRLD
----	---	--------	------------------	------------	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA		DR REDDYS LABS LTD	5MG/5ML	N78870 001	Apr 27, 2009	Apr	NEWA
----	--	--------------------	---------	------------	--------------	-----	------

CHLOROTHIAZIDE

TABLET; ORAL

DIURIL

	@	LUNDBECK INC	250MG	N11145 004		Apr	CAHN
--	---	--------------	-------	------------	--	-----	------

	@		500MG	N11145 002		Apr	CAHN
--	---	--	-------	------------	--	-----	------

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

DIURIL

+		LUNDBECK INC	EQ 500MG BASE/VIAL	N11145 005		Apr	CAHN
---	--	--------------	--------------------	------------	--	-----	------

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

	@	SANDOZ	100MG	N88725 001	Aug 31, 1984	Mar	DISC
--	---	--------	-------	------------	--------------	-----	------

	@		250MG	N88726 001	Aug 31, 1984	Mar	DISC
--	---	--	-------	------------	--------------	-----	------

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

	@ SANDOZ	250MG	N89852 001	May 04, 1988	Mar	DISC
	@	500MG	N89853 001	May 04, 1988	Mar	DISC
AA	WATSON LABS	500MG	N89859 001	May 04, 1988	Apr	CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

TRILIPIX

	ABBOTT LABS	EQ 45MG FENOFIBRIC ACID	N22224 001	Dec 15, 2008	Jan	CTNA
+		EQ 135MG FENOFIBRIC ACID	N22224 002	Dec 15, 2008	Jan	CTNA

CHYMOPAPAIN

INJECTABLE; INJECTION

CHYMODIACTIN

	@ CHART MEDCL	4,000 UNITS/VIAL	N18663 002	Aug 21, 1984	Mar	CAHN
	@	10,000 UNITS/VIAL	N18663 001	Nov 10, 1982	Mar	CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

	@ SANDOZ	200MG	N74100 001	Jan 31, 1995	Mar	DISC
	@	300MG	N74100 002	Jan 31, 1995	Mar	DISC
	@	400MG	N74100 003	Jan 31, 1995	Mar	DISC
	@	800MG	N74100 004	Jan 31, 1995	Mar	DISC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OTIC

CETRAXAL

>A>						
>A>	+	LABORATORIOS SALVAT	EQ 0.2% BASE	N21918 001	May 01, 2009	May NEWA

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB	MYLAN	EQ 250MG BASE	N75685 002	Jun 09, 2004	Mar	CMFD
AB		EQ 500MG BASE	N75685 003	Jun 09, 2004	Mar	CMFD
AB		EQ 750MG BASE	N75685 001	Jun 09, 2004	Mar	CMFD
	@ TEVA	EQ 250MG BASE	N76136 001	Jun 09, 2004	Jan	DISC
	@	EQ 500MG BASE	N76136 002	Jun 09, 2004	Jan	DISC
	@	EQ 750MG BASE	N76136 003	Jun 09, 2004	Jan	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	AMNEAL PHARMS	EQ 10MG BASE	N77045 003	Apr 29, 2005	Feb	CAHN
AB		EQ 20MG BASE	N77045 002	Apr 29, 2005	Feb	CAHN
AB		EQ 40MG BASE	N77045 001	Apr 29, 2005	Feb	CAHN
AB	GLENMARK GENERICS	EQ 10MG BASE	N77654 001	Feb 27, 2009	Feb	NEWA
AB		EQ 20MG BASE	N77654 002	Feb 27, 2009	Feb	NEWA
AB		EQ 40MG BASE	N77654 003	Feb 27, 2009	Feb	NEWA

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

	@ SANDOZ	0.1MG	N70887 001	Aug 31, 1988	Mar	DISC
	@	0.2MG	N70886 001	Aug 31, 1988	Mar	DISC

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

@ SANDOZ 0.3MG

N71294 001 Aug 31, 1988 Mar DISC

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

@ SANDOZ 3.75MG

N72219 001 Aug 26, 1988 Mar DISC

TRANXENE

@ LUNDBECK INC 3.75MG

N17105 001 Apr CAHN

@ 7.5MG

N17105 002 Apr CAHN

@ 15MG

N17105 003 Apr CAHN

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

@ SANDOZ 7.5MG

N72513 001 May 11, 1990 Mar DISC

@ 15MG

N72514 001 May 11, 1990 Mar DISC

TRANXENE

AB LUNDBECK INC 3.75MG

N17105 006 Apr CAHN

AB 7.5MG

N17105 007 Apr CAHN

AB + 15MG

N17105 008 Apr CAHN

>D> TRANXENE SD

>D> LUNDBECK INC 11.25MG

N17105 005 May DISC

>A> @ 11.25MG

N17105 005 May DISC

11.25MG

N17105 005 Apr CAHN

>D> + 22.5MG

N17105 004 May DISC

>A> @ 22.5MG

N17105 004 May DISC

+ 22.5MG

N17105 004 Apr CAHN

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIACIN-C

+ STI PHARMA LLC 10MG/5ML; 30MG/5ML; 1.25MG/5ML

N88704 001 Mar 22, 1985 Apr CAHN

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP PADDock EQ 150MG BASE/VIAL

N65177 001 Mar 19, 2004 Apr CTNA

AP X GEN PHARMS EQ 150MG BASE/VIAL

N64216 001 Feb 26, 1999 Apr CTNA

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

AN + TEVA PARENTERAL 10MG/ML

N75271 001 Jan 18, 2000 Apr CAHN

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL

@ PAR PHARM 0.5MG/INH

N19722 001 Nov 05, 1996 Mar CAHN

SPRAY, METERED; NASAL

NASCOBAL

>A> + PAR PHARM CO 0.5MG/SPRAY

N21642 001 Jan 31, 2005 May CAHN

>D> + QOL MEDCL 0.5MG/SPRAY

N21642 001 Jan 31, 2005 May CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

@ BAXTER HLTHCARE	100MG/VIAL	N12142 001		Feb	CAHN
@	200MG/VIAL	N12142 002		Feb	CAHN
@	500MG/VIAL	N12142 003		Feb	CAHN
@	1GM/VIAL	N12142 004	Aug 30, 1982	Feb	CAHN
@	2GM/VIAL	N12142 005	Aug 30, 1982	Feb	CAHN

LYOPHILIZED CYTOXAN

+	BAXTER HLTHCARE	100MG/VIAL	N12142 006	Dec 05, 1985	Feb	CAHN
+		200MG/VIAL	N12142 007	Dec 10, 1985	Feb	CAHN
AP	+	500MG/VIAL	N12142 008	Jan 04, 1984	Feb	CAHN
AP	+	1GM/VIAL	N12142 010	Sep 24, 1985	Feb	CAHN
AP	+	2GM/VIAL	N12142 009	Dec 10, 1984	Feb	CAHN

TABLET; ORAL

CYTOXAN

@ BAXTER HLTHCARE	25MG	N12141 002		Feb	CAHN
@	50MG	N12141 001		Feb	CAHN

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

+	LUNDBECK INC	0.5MG/VIAL	N50682 001		Apr	CAHN
---	--------------	------------	------------	--	-----	------

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

AP	WATSON LABS	500MG/VIAL	N76806 001	Mar 31, 2006	Apr	CAHN
AP		2GM/VIAL	N76806 002	Mar 31, 2006	Apr	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

DESOGESTREL AND ETHINYL ESTRADIOL

@ DURAMED PHARMS BARR	0.15MG;0.03MG	N75256 001	Aug 12, 1999	Feb	DISC
-----------------------	---------------	------------	--------------	-----	------

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA	+	STI PHARMA LLC	0.5MG/5ML	N84754 001		Apr	CAHN
----	---	----------------	-----------	------------	--	-----	------

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRADEX ST

+	ALCON	0.05%;0.3%	N50818 001	Feb 13, 2009	Feb	NEWA
---	-------	------------	------------	--------------	-----	------

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

KAPIDEX

	TAKEDA PHARMS	30MG	N22287 001	Jan 30, 2009	Jan	NEWA
+		60MG	N22287 002	Jan 30, 2009	Jan	NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	+	BARR	10MG	N40361 002	Jan 31, 2001	Mar	CRLD
----	---	------	------	------------	--------------	-----	------

TABLET; ORAL

DEXTROSTAT

@ SHIRE	5MG	N84051 001	Mar	DISC
@	10MG	N84051 002	Mar	DISC

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 60% IN PLASTIC CONTAINER

@ HOSPIRA	60GM/100ML	N19346 001	Jan 25, 1985	Apr	DISC
-----------	------------	------------	--------------	-----	------

DIAZEPAM

TABLET; ORAL

DIAZEPAM

@ SANDOZ	2MG	N70302 001	Dec 20, 1985	Mar	DISC
@	5MG	N70303 001	Dec 20, 1985	Mar	DISC
@	10MG	N70304 001	Dec 20, 1985	Mar	DISC

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

AA	COREPHARMA	25MG	N40828 001	Nov 05, 2008	Feb	CTEC
----	------------	------	------------	--------------	-----	------

TENUATE

AA	+	WATSON PHARMS	25MG	N11722 002	Feb	CTEC
----	---	---------------	------	------------	-----	------

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

@ SANDOZ	500MG	N74604 001	Jun 10, 1996	Mar	DISC
----------	-------	------------	--------------	-----	------

+	TEVA	500MG	N73673 001	Jul 31, 1992	Mar	CTEC
---	------	-------	------------	--------------	-----	------

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

@ HOSPIRA	0.25MG/ML	N40206 001	Aug 28, 1998	Apr	DISC
-----------	-----------	------------	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILT-CD

AB3	APOTEX	300MG	N76151 004	May 20, 2004	Apr	CAHN
-----	--------	-------	------------	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+	BARR	50MG	N80738 001	Mar	CRLD	
@	LNK	25MG	N87977 001	Jan 27, 1983	Mar	DISC
@		50MG	N87978 001	Jan 27, 1983	Mar	DISC
@	SANDOZ	25MG	N80832 001	Mar	DISC	
@		50MG	N80832 002	Mar	DISC	
@	VALEANT PHARM INTL	50MG	N80592 001	Mar	DISC	
@	WATSON LABS	25MG	N80728 001	Mar	DISC	
@		50MG	N80727 001	Mar	DISC	

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

@ SANDOZ	25MG	N86944 002	Apr 16, 1991	Mar	DISC
----------	------	------------	--------------	-----	------

TABLET; ORAL

DIPYRIDAMOLE

@ SANDOZ 50MG

N87562 001 Feb 25, 1992 Mar DISC

@ 75MG

N87561 001 Feb 25, 1992 Mar DISC

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DEPAKOTE

AB + ABBOTT EQ 125MG VALPROIC ACID

N19680 001 Sep 12, 1989 Jan CFTG

DIVALPROEX SODIUM

AB DR REDDYS LABS LTD EQ 125MG VALPROIC ACID

N78979 001 Jan 23, 2009 Jan NEWA

AB ZYDUS PHARMS USA INC EQ 125MG VALPROIC ACID

N78919 001 Jan 27, 2009 Jan NEWA

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

AB MYLAN EQ 125MG VALPROIC ACID

N90062 001 Mar 17, 2009 Mar NEWA

AB EQ 250MG VALPROIC ACID

N90062 002 Mar 17, 2009 Mar NEWA

AB EQ 500MG VALPROIC ACID

N90062 003 Mar 17, 2009 Mar NEWA

AB ZYDUS PHARMS USA INC EQ 125MG VALPROIC ACID

N77100 001 Mar 05, 2009 Feb NEWA

AB EQ 250MG VALPROIC ACID

N77100 002 Mar 05, 2009 Feb NEWA

AB EQ 500MG VALPROIC ACID

N77100 003 Mar 05, 2009 Feb NEWA

TABLET, EXTENDED RELEASE; ORAL

DEPAKOTE ER

AB ABBOTT EQ 250MG VALPROIC ACID

N21168 002 May 31, 2002 Jan CFTG

AB + EQ 500MG VALPROIC ACID

N21168 001 Aug 04, 2000 Jan CFTG

DIVALPROEX SODIUM

AB ANCHEN PHARMS EQ 250MG VALPROIC ACID

N78445 001 Feb 26, 2009 Feb NEWA

AB IMPAX LABS EQ 250MG VALPROIC ACID

N78791 001 May 06, 2009 Apr NEWA

AB MYLAN EQ 250MG VALPROIC ACID

N77567 001 Jan 29, 2009 Jan NEWA

AB EQ 500MG VALPROIC ACID

N77567 002 Jan 29, 2009 Jan NEWA

AB WOCKHARDT EQ 250MG VALPROIC ACID

N78705 002 Feb 10, 2009 Jan NEWA

AB ZYDUS PHARMS USA INC EQ 250MG VALPROIC ACID

N78239 001 Feb 27, 2009 Feb NEWA

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT ALCON EQ 2% BASE

N78981 001 Apr 13, 2009 Mar NEWA

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

+ PAR PHARM EQ 150MG BASE

N65055 003 Jul 15, 2005 Jan CRLD

TABLET; ORAL

DOXYCYCLINE

AB MUTUAL PHARM EQ 50MG BASE

N65471 001 Apr 17, 2009 Mar NEWA

AB EQ 75MG BASE

N65471 002 Apr 17, 2009 Mar NEWA

AB EQ 100MG BASE

N65471 003 Apr 17, 2009 Mar NEWA

DRONABINOL

CAPSULE; ORAL

DRONABINOL

AB SVC PHARMA 2.5MG

N78292 001 Jun 27, 2008 Mar CAHN

AB 5MG

N78292 002 Jun 27, 2008 Mar CAHN

AB 10MG

N78292 003 Jun 27, 2008 Mar CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	BARR	3MG;0.02MG	N78515 001	Mar 30, 2009	Mar	NEWA
YAZ						
AB	+ BAYER HLTHCARE	3MG;0.02MG	N21676 001	Mar 16, 2006	Mar	CFTG

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

@	SANDOZ	2.5MG	N75048 001	Aug 22, 2000	Mar	DISC
@		5MG	N75048 002	Aug 22, 2000	Mar	DISC
@		10MG	N75048 003	Aug 22, 2000	Mar	DISC
@		20MG	N75048 004	Aug 22, 2000	Mar	DISC

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXXEL

>D>	+ ASTRAZENECA	5MG;2.5MG	N20668 002	Oct 28, 1998	May	DISC
>A>	@	5MG;2.5MG	N20668 002	Oct 28, 1998	May	DISC

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP	+ HOSPIRA	1.25MG/ML	N75458 001	Aug 22, 2000	Feb	CRLD
VASOTEC						
	@ BIOVAIL LABS INTL	1.25MG/ML	N19309 001	Feb 09, 1988	Feb	DISC

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTAL

+	DENTSPLY PHARM	0.005MG/ML;4%	N21383 001		Apr	CTNA
---	----------------	---------------	------------	--	-----	------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

XYLOCAINE DENTAL WITH EPINEPHRINE

AP	+ DENTSPLY PHARM	0.01MG/ML;2%	N21381 001		Apr	CTNA
AP	+	0.02MG/ML;2%	N21381 002		Apr	CTNA
XYLOCAINE W/ EPINEPHRINE						
AP	+ APP PHARMS	0.02MG/ML;2%	N06488 005		Apr	CMFD

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

+	ACTELION	EQ 1.5MG BASE/VIAL	N22260 001	Jun 27, 2008	Apr	CAHN
---	----------	--------------------	------------	--------------	-----	------

ERGOCALCIFEROL

CAPSULE; ORAL

ERGOCALCIFEROL

>A>	AA	ORIT LABS LLC	50,000 IU	N40833 001	May 20, 2009	May	NEWA
-----	----	---------------	-----------	------------	--------------	-----	------

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE

@	ALPHARMA US PHARMS	EQ 125MG BASE/5ML	N62353 001	Nov 18, 1982	Apr	DISC
---	--------------------	-------------------	------------	--------------	-----	------

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE

@ ALPHARMA US PHARMS	EQ 250MG BASE/5ML	N62409 001	Dec 16, 1982	Apr	DISC
----------------------	-------------------	------------	--------------	-----	------

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

@ ALPHARMA US PHARMS	EQ 200MG BASE/5ML	N62200 001		Apr	DISC
----------------------	-------------------	------------	--	-----	------

@	EQ 400MG BASE/5ML	N62200 002		Apr	DISC
---	-------------------	------------	--	-----	------

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYZOLE

@ ALRA	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N62758 001	Jun 15, 1988	Jan	DISC
--------	--	------------	--------------	-----	------

PEDIAZOLE

@ ROSS LABS	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N50529 001		Jan	DISC
-------------	--	------------	--	-----	------

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

@ HOSPIRA	EQ 1GM BASE/VIAL	N50182 003		Feb	DISC
-----------	------------------	------------	--	-----	------

AP +	EQ 1GM BASE/VIAL	N62638 002	Oct 31, 1986	Feb	CRLD
------	------------------	------------	--------------	-----	------

ESTRADIOL

TABLET; ORAL

INNOFEM

@ NOVO NORDISK INC	0.5MG	N40312 001	Nov 19, 1999	Apr	DISC
--------------------	-------	------------	--------------	-----	------

@	1MG	N40312 002	Nov 19, 1999	Apr	DISC
---	-----	------------	--------------	-----	------

@	2MG	N40312 003	Nov 19, 1999	Apr	DISC
---	-----	------------	--------------	-----	------

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

MYAMBUTOL

AB	STI PHARMA LLC	100MG	N16320 001	Mar	CAHN
----	----------------	-------	------------	-----	------

@	200MG	N16320 002		Mar	CAHN
---	-------	------------	--	-----	------

AB		400MG	N16320 003	Mar	CAHN
----	--	-------	------------	-----	------

@	500MG	N16320 004		Mar	CAHN
---	-------	------------	--	-----	------

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

DEMULEN 1/35-21

@ GD SEARLE LLC	0.035MG;1MG	N18168 001		Apr	DISC
-----------------	-------------	------------	--	-----	------

DEMULEN 1/50-21

@ GD SEARLE LLC	0.05MG;1MG	N16927 001		Apr	DISC
-----------------	------------	------------	--	-----	------

ZOVIA 1/35E-21

@ WATSON LABS	0.035MG;1MG	N72720 001	Dec 30, 1991	Apr	DISC
---------------	-------------	------------	--------------	-----	------

ZOVIA 1/50E-21

@ WATSON LABS	0.05MG;1MG	N72722 001	Dec 30, 1991	Apr	DISC
---------------	------------	------------	--------------	-----	------

TABLET; ORAL-28

DEMULEN 1/35-28

@ GD SEARLE LLC	0.035MG;1MG	N18160 001		Apr	DISC
-----------------	-------------	------------	--	-----	------

DEMULEN 1/50-28

@ GD SEARLE LLC	0.05MG;1MG	N16936 001		Apr	DISC
-----------------	------------	------------	--	-----	------

TABLET; ORAL-28
ZOVIA 1/50E-28

+ WATSON LABS 0.05MG;1MG N72723 001 Dec 30, 1991 Apr CRLD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
TRIPHASIL-21

@ AKRIMAX PHARMS 0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG N19192 001 Nov 01, 1984 Apr CAHN

TABLET; ORAL-28
TRIPHASIL-28

@ WYETH PHARMS INC 0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG N19190 001 Nov 01, 1984 Apr DISC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS 0.035MG,0.035MG;0.5MG,1MG N71041 001 Sep 24, 1991 Apr CRLD

TABLET; ORAL-28
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

WATSON LABS 0.035MG,0.035MG;0.5MG,1MG N71044 001 Apr 01, 1988 Apr CTEC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21
LOESTRIN 21 1.5/30

AB WARNER CHILCOTT 0.03MG;1.5MG N17875 001 Apr CRLD

LOESTRIN 21 1/20

AB WARNER CHILCOTT 0.02MG;1MG N17876 001 Apr CRLD

TABLET; ORAL-28
LOESTRIN FE 1/20

AB WARNER CHILCOTT 0.02MG;1MG N17354 001 Apr CRLD

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21
OGESTREL 0.5/50-21

@ WATSON LABS 0.05MG;0.5MG N75406 001 Dec 15, 1999 Apr DISC

OVRAL

@ AKRIMAX PHARMS 0.05MG;0.5MG N16672 001 Mar CAHN

ETHOTOIN

TABLET; ORAL
PEGANONE

+ LUNDBECK INC 250MG

N10841 001 Apr CAHN

@ 500MG

N10841 003 Apr CAHN

ETOPOSIDE

CAPSULE; ORAL
ETOPOSIDE

+ GENPHARM 50MG

N75635 001 Sep 19, 2001 Feb CRLD

VEPESID

@ BRISTOL MYERS SQUIBB 50MG

N19557 001 Dec 30, 1986 Feb DISC

EVEROLIMUS

TABLET; ORAL
AFINITOR

NOVARTIS 5MG

N22334 001 Mar 30, 2009 Mar NEWA

TABLET; ORAL

AFINITOR

+	NOVARTIS	10MG	N22334 002	Mar 30, 2009	Mar	NEWA
---	----------	------	------------	--------------	-----	------

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

>A>	AB	ALEMBIC LTD	20MG	N78916 001	May 22, 2009	May	NEWA
>A>	AB		40MG	N78916 002	May 22, 2009	May	NEWA
		@ SANDOZ	20MG	N75302 001	Apr 16, 2001	Mar	DISC
		@	40MG	N75302 002	Apr 16, 2001	Mar	DISC

FEBUXOSTAT

TABLET; ORAL

ULORIC

		TAKEDA PHARMS	40MG	N21856 001	Feb 13, 2009	Feb	NEWA
+			80MG	N21856 002	Feb 13, 2009	Feb	NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

		@ PEDINOL	EQ 300MG BASE	N17604 002		Feb	DISC
		NALFON 200					
+		PEDINOL	EQ 200MG BASE	N17604 003		Feb	CRLD

TABLET; ORAL

FENOPROFEN CALCIUM

		@ SANDOZ	EQ 600MG BASE	N72396 001	Oct 17, 1988	Mar	DISC
--	--	----------	---------------	------------	--------------	-----	------

FENTANYL CITRATE

INJECTABLE; INJECTION

SUBLIMAZE PRESERVATIVE FREE

>A>	AP	+	AKORN	EQ 0.05MG BASE/ML	N16619 001		May	CAHN
>D>	AP	+	AKORN MFG	EQ 0.05MG BASE/ML	N16619 001		May	CAHN

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

		@ SANDOZ	50MG	N76030 001	Oct 28, 2002	Mar	DISC
		@	100MG	N76030 002	Oct 28, 2002	Mar	DISC
		@	150MG	N76030 003	Oct 28, 2002	Mar	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

AP		ACTAVIS TOTOWA	50MG/VIAL	N78610 001	Feb 11, 2009	Feb	NEWA
----	--	----------------	-----------	------------	--------------	-----	------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP		HIKMA FARMACEUTICA	0.5MG/5ML (0.1MG/ML)	N78527 001	Mar 23, 2009	Mar	NEWA
AP			1MG/10ML (0.1MG/ML)	N78527 002	Mar 23, 2009	Mar	NEWA

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

DERMA-SMOOTH/FS

+		HILL DERMAC	0.01%	N19452 002	Nov 09, 2005	Feb	NEWA
---	--	-------------	-------	------------	--------------	-----	------

FLUOROURACIL

SOLUTION; TOPICAL

FLUOROPLEX

@ ELORAC

1%

N16765 001

Feb CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1	ALEMBIC LTD	EQ 10MG BASE	N90223 001	Mar 19, 2009	Mar	NEWA
AB1		EQ 20MG BASE	N90223 002	Mar 19, 2009	Mar	NEWA
AB		EQ 40MG BASE	N90223 003	Mar 19, 2009	Mar	NEWA
AB1	BEIJING DOUBLE CRANE	EQ 10MG BASE	N76165 001	Feb 01, 2002	Mar	CAHN
AB1		EQ 20MG BASE	N76165 002	Feb 01, 2002	Mar	CAHN

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

AA	AUROBINDO PHARM	EQ 20MG BASE/5ML	N79209 001	Mar 20, 2009	Mar	NEWA
----	-----------------	------------------	------------	--------------	-----	------

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

AB	MYLAN	EQ 10MG BASE	N75755 001	Aug 02, 2001	Apr	CAHN
+		EQ 20MG BASE	N75755 002	Aug 02, 2001	Apr	CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

@ SANDOZ

15MG

N71716 001 Jul 31, 1991 Mar DISC

@

30MG

N71717 001 Jul 31, 1991 Mar DISC

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

@ SANDOZ

50MG

N74448 001 Jul 28, 1995 Mar DISC

@

100MG

N74448 002 Jul 28, 1995 Mar DISC

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@ IVAX PHARMS

25MG

N75898 001 Mar 12, 2001 Mar DISC

@

50MG

N75898 002 Mar 12, 2001 Mar DISC

@

100MG

N75898 003 Mar 12, 2001 Mar DISC

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

AP	GENERAMEDIX	1.5GM/1.5ML (1GM/ML)	N79033 001	Apr 07, 2009	Mar	NEWA
----	-------------	----------------------	------------	--------------	-----	------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@ SANDOZ

10MG

N76188 001 Oct 08, 2004 Mar DISC

@

20MG

N76188 002 Oct 08, 2004 Mar DISC

@

40MG

N76188 003 Oct 08, 2004 Mar DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

MONOPRIL-HCT

@ BRISTOL MYERS SQUIBB 10MG;12.5MG
 @ 20MG;12.5MG

N20286 002 Nov 30, 1994 Feb DISC
 N20286 001 Nov 30, 1994 Feb DISC

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

>A> AB IMPAX LABS EQ 8MG BASE
 >A> AB EQ 16MG BASE
 >A> AB EQ 24MG BASE

N78484 001 May 27, 2009 May NEWA
 N78484 002 May 27, 2009 May NEWA
 N78484 003 May 27, 2009 May NEWA

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE

AA ROXANE 4MG/ML

N78185 001 Jan 30, 2009 Jan NEWA

RAZADYNE

AA + ORTHO MCNEIL JANSSEN 4MG/ML

N21224 001 Jun 22, 2001 Jan CFTG

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB BEJING YABAO EQ 4MG BASE
 AB EQ 8MG BASE
 AB EQ 12MG BASE
 >A> AB MYLAN EQ 4MG BASE
 AB EQ 4MG BASE
 >A> AB EQ 8MG BASE
 AB EQ 8MG BASE
 >A> AB EQ 12MG BASE
 AB EQ 12MG BASE
 AB PAR PHARM EQ 4MG BASE
 AB EQ 8MG BASE
 AB EQ 12MG BASE
 AB ROXANE EQ 4MG BASE
 AB EQ 8MG BASE
 AB EQ 12MG BASE

N77604 001 Feb 06, 2009 Apr CAHN
 N77604 002 Feb 06, 2009 Apr CAHN
 N77604 003 Feb 06, 2009 Apr CAHN
 N77590 001 May 29, 2009 May NEWA
 N77603 001 Aug 28, 2008 Apr CAHN
 N77590 002 May 29, 2009 May NEWA
 N77603 002 Aug 28, 2008 Apr CAHN
 N77590 003 May 29, 2009 May NEWA
 N77603 003 Aug 28, 2008 Apr CAHN
 N77604 001 Feb 06, 2009 Jan NEWA
 N77604 002 Feb 06, 2009 Jan NEWA
 N77604 003 Feb 06, 2009 Jan NEWA
 N77608 001 Feb 11, 2009 Jan NEWA
 N77608 002 Feb 11, 2009 Jan NEWA
 N77608 003 Feb 11, 2009 Jan NEWA

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT

>D> TAKEDA GLOBAL 2MG;30MG
 >A> + 2MG;30MG
 >D> + 4MG;30MG
 >A> 4MG;30MG

N21925 001 Jul 28, 2006 May CRLD
 N21925 001 Jul 28, 2006 May CRLD
 N21925 002 Jul 28, 2006 May CRLD
 N21925 002 Jul 28, 2006 May CRLD

GLYBURIDE

TABLET; ORAL

GLYBURIDE

AB + TEVA 5MG

N74388 003 Aug 29, 1995 Mar CRLD

MICRONASE

@ PHARMACIA AND UPJOHN 1.25MG
 @ 2.5MG
 @ 5MG

N17498 001 May 01, 1984 Mar DISC
 N17498 002 May 01, 1984 Mar DISC
 N17498 003 May 01, 1984 Mar DISC

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

>D>	AB	BRISTOL MYERS SQUIBB	2.5MG;500MG	N21178 002	Jul 31, 2000	May	CRLD
>A>	AB	+	2.5MG;500MG	N21178 002	Jul 31, 2000	May	CRLD
>D>	AB	+	5MG;500MG	N21178 003	Jul 31, 2000	May	CRLD
>A>	AB		5MG;500MG	N21178 003	Jul 31, 2000	May	CRLD

GLYBURIDE AND METFORMIN HYDROCHLORIDE

>A>	AB	DR REDDYS LABS INC	1.25MG;250MG	N79009 001	Jun 03, 2009	May	NEWA
>A>	AB		2.5MG;500MG	N79009 002	Jun 03, 2009	May	NEWA
>A>	AB		5MG;500MG	N79009 003	Jun 03, 2009	May	NEWA

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA		WEST WARD	1MG	N40836 001	Mar 05, 2009	Feb	NEWA
AA			2MG	N40836 002	Mar 05, 2009	Feb	NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP		SANDOZ	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N78534 001	Apr 30, 2009	Apr	NEWA
AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N78531 001	Apr 30, 2009	Apr	NEWA
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N78531 002	Apr 30, 2009	Apr	NEWA

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

AB		DR REDDYS LABS LTD	EQ 1MG BASE	N78846 001	Feb 27, 2009	Feb	NEWA
----	--	--------------------	-------------	------------	--------------	-----	------

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

@	SANDOZ	EQ 50MG BASE/ML	N76463 001	Jun 24, 2005	Apr	DISC
@		EQ 100MG BASE/ML	N76463 002	Jun 24, 2005	Apr	DISC

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

@	SANDOZ	EQ 5MG BASE/ML	N76464 001	Sep 29, 2004	Apr	DISC
---	--------	----------------	------------	--------------	-----	------

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

+	ENDO PHARM	50MG	N22058 001	May 03, 2007	Apr	CAHN
---	------------	------	------------	--------------	-----	------

VANTAS

+	ENDO PHARM	50MG	N21732 001	Oct 12, 2004	Apr	CAHN
---	------------	------	------------	--------------	-----	------

+	ENDO PHARMS	50MG	N21732 001	Oct 12, 2004	Mar	CAHN
---	-------------	------	------------	--------------	-----	------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

@	ENDO PHARMS	1.5MG/5ML;5MG/5ML	N05213 002	Jul 26, 1988	Feb	DISC
---	-------------	-------------------	------------	--------------	-----	------

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	+	HI TECH PHARMA	1.5MG/5ML;5MG/5ML	N40613 001	Feb 08, 2008	Feb	CRLD
----	---	----------------	-------------------	------------	--------------	-----	------

TABLET; ORAL

HYCODAN

@ ENDO PHARMS

1.5MG;5MG

N05213 001 Jul 26, 1988 Feb DISC

TUSSIGON

AA + KING PHARMS

1.5MG;5MG

N88508 001 Jul 30, 1985 Feb CRLD

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP AKORN

20MG/ML

N40730 001 Apr 21, 2009 Mar NEWA

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>A> AA

GLENMARK PHARMS LTD

10MG

N90527 001 May 27, 2009 May NEWA

>A> AA

25MG

N90527 002 May 27, 2009 May NEWA

>A> AA

50MG

N90527 003 May 27, 2009 May NEWA

>A> AA

100MG

N90527 004 May 27, 2009 May NEWA

@ SANDOZ

10MG

N83241 001 Mar DISC

@

25MG

N83560 001 Mar DISC

@

50MG

N83561 001 Mar DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB IPCA LABS LTD

12.5MG

N79237 001 Apr 02, 2009 Mar NEWA

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE

@ ROXANE

50MG/5ML

N88587 001 Jul 02, 1984 Mar DISC

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@ SANDOZ

25MG

N87565 001 Mar 09, 1982 Mar DISC

@

50MG

N84912 001 Mar DISC

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ SANDOZ

25MG;40MG

N71060 001 Aug 26, 1987 Mar DISC

@

25MG;80MG

N71061 001 Aug 26, 1987 Mar DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB RANBAXY

12.5MG;EQ 10MG BASE

N78211 001 Mar 04, 2009 Feb NEWA

AB

12.5MG;EQ 20MG BASE

N78211 002 Mar 04, 2009 Feb NEWA

AB

25MG;EQ 20MG BASE

N78211 003 Mar 04, 2009 Feb NEWA

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

@ SANDOZ

25MG;25MG

N86881 001 Mar DISC

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION; OPHTHALMIC

TERRA-CORTIL

@ PFIZER

1.5%;EQ 5MG BASE/ML

N61016 001 Feb DISC

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL
PROCTOFOAM HC

BX	UCB INC	1%;1%	N86195 001	Apr	CAHN
----	---------	-------	------------	-----	------

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL
CARMOL HC

AT	+	NYCOMED US	1%;10%	N80505 001	Apr	CAHN
----	---	------------	--------	------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
DILAUDID

>D>		PURDUE PHARM PRODS	1MG/ML	N19034 003	Apr 30, 2009	May	CMFD
>A>	+		1MG/ML	N19034 003	Apr 30, 2009	May	CMFD
			1MG/ML	N19034 003	Apr 30, 2009	Apr	NEWA
>D>			2MG/ML	N19034 004	Apr 30, 2009	May	CRLD
>A>	+		2MG/ML	N19034 004	Apr 30, 2009	May	CRLD
			2MG/ML	N19034 004	Apr 30, 2009	Apr	NEWA
>D>			4MG/ML	N19034 005	Apr 30, 2009	May	CRLD
>A>	+		4MG/ML	N19034 005	Apr 30, 2009	May	CRLD
			4MG/ML	N19034 005	Apr 30, 2009	Apr	NEWA

TABLET; ORAL
HYDROMORPHONE HYDROCHLORIDE

>A>	AB	ROXANE	4MG	N74597 003	May 29, 2009	May	NEWA
-----	----	--------	-----	------------	--------------	-----	------

HYDROXYUREA

CAPSULE; ORAL
HYDROXYUREA

AB		BARR	500MG	N75143 001	Oct 16, 1998	Feb	CMFD
----	--	------	-------	------------	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HYDROCHLORIDE

@	SANDOZ	10MG	N87869 001	Dec 20, 1982	Mar	DISC
@		25MG	N87870 001	Dec 20, 1982	Mar	DISC
@		50MG	N87871 001	Dec 20, 1982	Mar	DISC

HYDROXYZINE PAMOATE

CAPSULE; ORAL
HYDROXYZINE PAMOATE
@ SANDOZ

EQ 25MG HCL	N81127 001	Jun 28, 1991	Mar	DISC
-------------	------------	--------------	-----	------

IBUPROFEN

TABLET; ORAL
IBUPROFEN

AB	+	DR REDDYS LA	800MG	N75682 003	Nov 14, 2001	Feb	CRLD
		@ SANDOZ	300MG	N70734 001	Jun 12, 1986	Mar	DISC
		@	400MG	N70735 001	Jun 12, 1986	Mar	DISC
		@	600MG	N70736 001	Jun 12, 1986	Mar	DISC
		@	800MG	N72169 001	Dec 11, 1987	Mar	DISC
AB		SHASUN USA	400MG	N78329 001	Feb 05, 2009	Jan	NEWA
AB			600MG	N78329 002	Feb 05, 2009	Jan	NEWA
AB			800MG	N78329 003	Feb 05, 2009	Jan	NEWA

TABLET; ORAL

MOTRIN

@ MCNEIL CONSUMER	300MG	N17463 003	Apr	DISC
@	400MG	N17463 002	Feb	DISC
@	600MG	N17463 004	Feb	DISC
@	800MG	N17463 005	May 22, 1985	Feb DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ LUNDBECK INC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N21903 001	Apr 13, 2006	Apr CAHN
----------------	------------------------------------	------------	--------------	----------

IFOSFAMIDE

INJECTABLE; INJECTION

IFEX

@ BAXTER HLTHCARE	1GM/VIAL	N19763 001	Dec 30, 1988	Feb CAHN
@	3GM/VIAL	N19763 002	Dec 30, 1988	Feb CAHN

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

+ BAXTER HLTHCARE	1GM/VIAL;100MG/ML	N19763 003	Oct 10, 1992	Feb CAHN
+	3GM/VIAL;100MG/ML	N19763 004	Oct 10, 1992	Feb CAHN

>A> ILOPERIDONE

>A> TABLET; ORAL

>A> FANAPT

>A>	VANDA PHARMS INC	1MG	N22192 001	May 06, 2009	May NEWA
>A>		2MG	N22192 002	May 06, 2009	May NEWA
>A>		4MG	N22192 003	May 06, 2009	May NEWA
>A>		6MG	N22192 004	May 06, 2009	May NEWA
>A>		8MG	N22192 005	May 06, 2009	May NEWA
>A>		10MG	N22192 006	May 06, 2009	May NEWA
>A>	+	12MG	N22192 007	May 06, 2009	May NEWA

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR

AB	+ SANDOZ	75MG	N74464 001	May 28, 1998	Feb CTEC
----	----------	------	------------	--------------	----------

INDOMETHACIN

AB	AVANTHI INC	75MG	N79175 001	Mar 06, 2009	Feb NEWA
----	-------------	------	------------	--------------	----------

SUSPENSION; ORAL

INDOCIN

+	IROKO PHARMS	25MG/5ML	N18332 001	Oct 10, 1985	Mar CAHN
---	--------------	----------	------------	--------------	----------

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP	+ LUNDBECK INC	EQ 1MG BASE/VIAL	N18878 001	Jan 30, 1985	Apr CAHN
----	----------------	------------------	------------	--------------	----------

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA SOLOSTAR

	SANOFI AVENTIS US	300 UNITS/3ML	N21629 003	Feb 24, 2009	Feb NEWA
--	-------------------	---------------	------------	--------------	----------

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

AN	TEVA PARENTERAL	0.02%	N75313 001	Feb 07, 2000	Apr	CAHN
----	-----------------	-------	------------	--------------	-----	------

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	PHARMAFORCE	40MG/2ML (20MG/ML)	N90016 001	Jan 28, 2009	Mar	NEWA
AP		40MG/2ML (20MG/ML)	N90016 001	Jan 28, 2009	Jan	NEWA
AP		100MG/5ML (20MG/ML)	N90016 002	Jan 28, 2009	Mar	NEWA
AP		100MG/5ML (20MG/ML)	N90016 002	Jan 28, 2009	Jan	NEWA

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

@ SANDOZ 2.5MG

N86225 001 Feb 19, 1988 Mar DISC

@ 5MG

N86222 001 Feb 19, 1988 Mar DISC

KETOCONAZOLE

GEL; TOPICAL

XOLEGEL

+ STIEFEL LABS INC 2%

N21946 001 Jul 28, 2006 Jan CAHN

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

@ SANDOZ 50MG

N74024 001 Dec 29, 1995 Mar DISC

@ 75MG

N74024 002 Dec 29, 1995 Mar DISC

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	APOTEX INC	25MG	N78625 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78625 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78625 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78625 004	Jan 27, 2009	Jan	NEWA
AB	AUROBINDO PHARMA	25MG	N78956 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78956 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78956 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78956 004	Jan 27, 2009	Jan	NEWA
AB	CADISTA PHARMS	25MG	N79132 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N79132 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N79132 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N79132 004	Jan 27, 2009	Jan	NEWA
AB	DR REDDYS LABS LTD	25MG	N76708 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N76708 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N76708 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N76708 004	Jan 27, 2009	Jan	NEWA
AB	GENPHARM ULC	25MG	N77428 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77428 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77428 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77428 004	Jan 27, 2009	Jan	NEWA
AB	MATRIX LABS LTD	25MG	N78443 001	Feb 11, 2009	Jan	NEWA
AB		100MG	N78443 002	Feb 11, 2009	Jan	NEWA

TABLET; ORAL

LAMOTRIGINE

AB	MATRIX LABS LTD	150MG	N78443 003	Feb 11, 2009	Jan	NEWA
AB		200MG	N78443 004	Feb 11, 2009	Jan	NEWA
AB	MYLAN	25MG	N77420 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77420 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77420 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77420 004	Jan 27, 2009	Jan	NEWA
AB	ROXANE	25MG	N77392 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77392 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77392 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77392 004	Jan 27, 2009	Jan	NEWA
AB	SANDOZ	25MG	N78645 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78645 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78645 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78645 004	Jan 27, 2009	Jan	NEWA
AB	TARO PHARM INDS	25MG	N78525 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78525 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78525 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78525 004	Jan 27, 2009	Jan	NEWA
AB	TORRENT PHARMS	25MG	N78947 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78947 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78947 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78947 004	Jan 27, 2009	Jan	NEWA
AB	UPSHER SMITH	25MG	N78310 001	Feb 04, 2009	Jan	NEWA
AB		100MG	N78310 002	Feb 04, 2009	Jan	NEWA
AB		150MG	N78310 003	Feb 04, 2009	Jan	NEWA
AB		200MG	N78310 004	Feb 04, 2009	Jan	NEWA
AB	WOCKHARDT	25MG	N78982 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78982 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78982 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78982 004	Jan 27, 2009	Jan	NEWA
AB	ZYDUS PHARMS USA	25MG	N77633 001	Jan 27, 2009	Jan	NEWA
		50MG	N77633 002	Jan 27, 2009	Jan	NEWA
AB		100MG	N77633 003	Jan 27, 2009	Jan	NEWA
AB		150MG	N77633 004	Jan 27, 2009	Jan	NEWA
AB		200MG	N77633 005	Jan 27, 2009	Jan	NEWA
		250MG	N77633 006	Jan 27, 2009	Jan	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB	GLENMARK GENERICS	5MG	N79099 001	Feb 19, 2009	Feb	NEWA
AB		25MG	N79099 002	Feb 19, 2009	Feb	NEWA
AB	TARO	5MG	N79204 001	Feb 04, 2009	Jan	NEWA
AB		25MG	N79204 002	Feb 04, 2009	Jan	NEWA

>A> TABLET, EXTENDED RELEASE; ORAL

>A> LAMICTAL XR

>A>	SMITHKLINE BEECHAM	25MG	N22115 001	May 29, 2009	May	NEWA
>A>		50MG	N22115 002	May 29, 2009	May	NEWA
>A>		100MG	N22115 003	May 29, 2009	May	NEWA
>A>	+	200MG	N22115 004	May 29, 2009	May	NEWA

>A> TABLET, ORALLY DISINTEGRATING; ORAL

>A> LAMICTAL ODT

>A>	SMITHKLINE BEECHAM	25MG	N22251 001	May 08, 2009	May	NEWA
>A>		50MG	N22251 002	May 08, 2009	May	NEWA
>A>		100MG	N22251 003	May 08, 2009	May	NEWA
>A>	+	200MG	N22251 004	May 08, 2009	May	NEWA

LANSOPRAZOLE

>D>	FOR SUSPENSION, DELAYED RELEASE; ORAL			
>D>	PREVACID			
>D>	TAKEDA PHARMS NA	15MG/PACKET	N21281 001	May 03, 2001 May DISC
>A>	@	15MG/PACKET	N21281 001	May 03, 2001 May DISC
>D>	+	30MG/PACKET	N21281 002	May 03, 2001 May DISC
>A>	@	30MG/PACKET	N21281 002	May 03, 2001 May DISC

LEUCOVORIN CALCIUM

TABLET; ORAL				
LEUCOVORIN CALCIUM				
>D>	BX	XANODYNE PHARM	EQ 5MG BASE	N18459 001 Jan 30, 1986 May DISC
>A>	@		EQ 5MG BASE	N18459 001 Jan 30, 1986 May DISC

LEUPROLIDE ACETATE

INJECTABLE; INJECTION				
LEUPROLIDE ACETATE				
AP		SUN PHARMA GLOBAL	1MG/0.2ML	N78885 001 Mar 09, 2009 Feb NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION				
LEVALBUTEROL HYDROCHLORIDE				
AN		DEY	EQ 0.25% BASE	N78309 001 Mar 20, 2009 Mar NEWA
XOPENEX				
AN	+	SEPRACOR	EQ 0.25% BASE	N20837 004 Jul 18, 2003 Mar CFTG

LEVETIRACETAM

SOLUTION; ORAL				
LEVETIRACETAM				
AA		SILARX	100MG/ML	N90263 001 Apr 03, 2009 Mar NEWA
AA		TARO	100MG/ML	N78774 001 Feb 10, 2009 Jan NEWA
TABLET; ORAL				
LEVETIRACETAM				
AB		APOTEX INC	250MG	N78869 001 Mar 13, 2009 Mar NEWA
AB			500MG	N78869 002 Mar 13, 2009 Mar NEWA
AB			750MG	N78869 003 Mar 13, 2009 Mar NEWA
AB			1GM	N78869 004 Mar 13, 2009 Mar NEWA
AB		CIPLA LTD	250MG	N77319 001 Mar 20, 2009 Mar NEWA
AB			500MG	N77319 002 Mar 20, 2009 Mar NEWA
AB			750MG	N77319 003 Mar 20, 2009 Mar NEWA
AB		GENPHARM ULC	250MG	N78731 001 Feb 10, 2009 Jan NEWA
AB			500MG	N78731 002 Feb 10, 2009 Jan NEWA
AB			750MG	N78731 003 Feb 10, 2009 Jan NEWA
AB			1GM	N78731 004 Feb 10, 2009 Jan NEWA
AB		SOLCO HLTHCARE	250MG	N78106 001 Feb 10, 2009 Jan NEWA
AB			500MG	N78106 002 Feb 10, 2009 Jan NEWA
AB			750MG	N78106 003 Feb 10, 2009 Jan NEWA
AB			1GM	N78106 004 Feb 10, 2009 Jan NEWA
AB		WATSON LABS FLORIDA	250MG	N77408 001 Mar 02, 2009 Feb NEWA
AB			500MG	N77408 002 Mar 02, 2009 Feb NEWA
AB			750MG	N77408 003 Mar 02, 2009 Feb NEWA
AB		ZYDUS PHARMS USA INC	250MG	N78918 001 Apr 29, 2009 Apr NEWA
AB			1GM	N78918 002 Apr 29, 2009 Apr NEWA

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

UCB INC

500MG

N22285 001 Sep 12, 2008 Feb CRLD

+

750MG

N22285 002 Feb 12, 2009 Feb NEWA

LEVOFLOXACIN

TABLET; ORAL

LEVAQUIN

AB ORTHO MCNEIL JANSSEN 250MG

N20634 001 Dec 20, 1996 Apr CFTG

AB 500MG

N20634 002 Dec 20, 1996 Apr CFTG

AB + 750MG

N20634 003 Sep 08, 2000 Apr CFTG

LEVOFLOXACIN

AB LUPIN 250MG

N78424 001 May 13, 2009 Apr NEWA

AB 500MG

N78424 002 May 13, 2009 Apr NEWA

AB 750MG

N78424 003 May 13, 2009 Apr NEWA

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL

LEVOTHYROXINE SODIUM

AB2, MERCK KGAA 0.025MG

N76752 001 Jun 16, 2005 Apr CAHN

AB3

AB2, 0.05MG

N76752 002 Jun 16, 2005 Apr CAHN

AB3

AB2, 0.075MG

N76752 003 Jun 16, 2005 Apr CAHN

AB3

AB2, 0.088MG

N76752 004 Jun 16, 2005 Apr CAHN

AB3

AB2, 0.1MG

N76752 005 Jun 16, 2005 Apr CAHN

AB3

AB2, 0.112MG

N76752 006 Jun 16, 2005 Apr CAHN

AB3

AB2, 0.125MG

N76752 007 Jun 16, 2005 Apr CAHN

AB3

AB2, 0.15MG

N76752 008 Jun 16, 2005 Apr CAHN

AB3

AB2, 0.175MG

N76752 009 Jun 16, 2005 Apr CAHN

AB3

AB2, 0.2MG

N76752 010 Jun 16, 2005 Apr CAHN

AB3

AB2, 0.3MG

N76752 011 Jun 16, 2005 Apr CAHN

AB3

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

@ HOSPIRA

10%

N88367 001 Jul 31, 1984 Apr DISC

XYLOCAINE

AP + APP PHARMS 2%

N06488 002 Apr CMFD

XYLOCAINE DENTAL

AP + DENTSPLY PHARM 2%

N21380 001 Apr CTNA

>D> SYSTEM; INTRADERMAL

>D> ZINGO

>D> + ANESIVA 0.5MG

N22114 001 Aug 16, 2007 May DISC

>A> @ 0.5MG

N22114 001 Aug 16, 2007 May DISC

LINDANE

LOTION; TOPICAL

LINDANE

@ OLTA PHARMS

1%

N87313 001 Apr CAHN

SHAMPOO; TOPICAL									
LINDANE									
AT	+	OLTA PHARMS	1%		N87266 001		Jan	CAHN	
<u>LIOTHYRONINE SODIUM</u>									
TABLET; ORAL									
CYTOMEL									
AB		KING PHARMS	EQ 0.005MG BASE		N10379 001		Mar	CFTG	
AB			EQ 0.025MG BASE		N10379 002		Mar	CTEC	
AB	+		EQ 0.05MG BASE		N10379 003		Mar	CTEC	
LIOTHYRONINE SODIUM									
AB		COASTAL PHARMS	EQ 0.005MG BASE		N90097 001	Mar 20, 2009	Mar	NEWA	
AB			EQ 0.025MG BASE		N90097 002	Mar 20, 2009	Mar	NEWA	
AB			EQ 0.05MG BASE		N90097 003	Mar 20, 2009	Mar	NEWA	
<u>LITHIUM CARBONATE</u>									
CAPSULE; ORAL									
LITHIUM CARBONATE									
AB		GLENMARK GENERICS	150MG		N79139 001	Feb 03, 2009	Jan	NEWA	
AB			300MG		N79139 002	Feb 03, 2009	Jan	NEWA	
AB			600MG		N79139 003	Feb 03, 2009	Jan	NEWA	
<u>LOPERAMIDE HYDROCHLORIDE</u>									
CAPSULE; ORAL									
LOPERAMIDE HYDROCHLORIDE									
		@ SANDOZ	2MG		N72993 001	Aug 28, 1992	Mar	DISC	
<u>LORAZEPAM</u>									
CONCENTRATE; ORAL									
LORAZEPAM									
AA		PADDOCK LABS	2MG/ML		N79244 001	Apr 28, 2009	Apr	NEWA	
LORAZEPAM INTENSOL									
AA	+	ROXANE	2MG/ML		N72755 001	Jun 28, 1991	Apr	CFTG	
SOLUTION; ORAL									
LORAZEPAM									
		@ ROXANE	0.5MG/5ML		N74648 001	Mar 18, 1997	Mar	DISC	
<u>MALATHION</u>									
LOTION; TOPICAL									
MALATHION									
AT		SYNERX PHARMA	0.5%		N78743 001	Mar 06, 2009	Feb	NEWA	
OVIDE									
AT	+	TARO PHARMS NORTH	0.5%		N18613 001	Aug 02, 1982	Feb	CFTG	
<u>MECHLORETHAMINE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
MUSTARGEN									
	+	LUNDBECK INC	10MG/VIAL		N06695 001		Apr	CAHN	
<u>MECLIZINE HYDROCHLORIDE</u>									
TABLET; ORAL									
ANTIVERT									
AA	+	PFIZER	12.5MG		N10721 006		Jan	CAHN	
AA	+		25MG		N10721 004		Jan	CAHN	
AA	+		50MG		N10721 001	Jan 20, 1982	Jan	CAHN	

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

@ SANDOZ EQ 50MG BASE
 @ EQ 100MG BASE

N72262 001 Nov 29, 1988 Mar DISC
 N72263 001 Nov 29, 1988 Mar DISC

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

>A> AB SANDOZ 150MG/ML

N78711 001 May 20, 2009 May NEWA

MELOXICAM

TABLET; ORAL

MELOXICAM

AB BEJING YABAO 7.5MG
 AB 15MG
 >A> AB STRIDES ARCOLAB LTD 7.5MG
 >A> AB 15MG

N77933 001 Jul 19, 2006 Apr CAHN
 N77933 002 Jul 19, 2006 Apr CAHN
 N77928 001 May 13, 2009 May NEWA
 N77928 002 May 13, 2009 May NEWA

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

AA ALEMBIC LTD 200MG
 AA 400MG
 @ IVC INDS 400MG

N90122 001 Feb 18, 2009 Feb NEWA
 N90122 002 Feb 18, 2009 Feb NEWA
 N84153 001 Apr CAHN

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

+ STIEFEL LABS INC 2%;0.01%

N20922 001 Dec 10, 1999 Jan CAHN

MESALAMINE

TABLET, DELAYED RELEASE; ORAL

>A> ASACOL
 >A> + PROCTER AND GAMBLE 800MG
 >D> MESALAMINE
 >D> + PROCTOR AND GAMBLE 800MG

N21830 001 May 29, 2008 May CTNA
 N21830 001 May 29, 2008 May CTNA

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/50M-21

@ WATSON LABS 0.05MG;1MG

N71539 001 Apr 12, 1988 Apr DISC

NORETHINDRONE AND MESTRANOL

@ WATSON LABS 0.05MG;1MG

N70758 001 Jul 01, 1988 Apr DISC

NORINYL 1+50 21-DAY

@ WATSON LABS 0.05MG;1MG

N13625 002 Apr DISC

TABLET; ORAL-28

NORETHIN 1/50M-28

@ WATSON LABS 0.05MG;1MG

N71540 001 Apr 12, 1988 Apr DISC

NORETHINDRONE AND MESTRANOL

@ WATSON LABS 0.05MG;1MG

N70759 001 Jul 01, 1988 Apr DISC

NORINYL 1+50 28-DAY

+ WATSON LABS 0.05MG;1MG

N16659 001 Apr CRLD

ORTHO-NOVUM 1/50 28

@ ORTHO MCNEIL JANSSEN 0.05MG;1MG

N16709 001 Apr DISC

METAPROTERENOL SULFATE

SOLUTION; INHALATION

ALUPENT

@ BOEHRINGER INGELHEIM 0.4%

N18761 002 Oct 10, 1986 Feb DISC

@ 0.6%

N18761 001 Jun 30, 1983 Feb DISC

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB ALVOGEN 500MG

N76033 001 Jan 24, 2002 Jan CAHN

AB 850MG

N76033 002 Jan 24, 2002 Jan CAHN

AB 1GM

N76033 003 Jan 24, 2002 Jan CAHN

AB PROVIDENT PHARM 500MG

N77853 001 Jul 28, 2006 Apr CAHN

AB 850MG

N77853 002 Jul 28, 2006 Apr CAHN

AB 1GM

N77853 003 Jul 28, 2006 Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

@ SANDOZ 500MG

N76223 001 Dec 14, 2004 Mar DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

>A> TABLET, EXTENDED RELEASE; ORAL

>A> ACTOPLUS MET XR

>A> TAKEDA GLOBAL 1GM;EQ 15MG BASE

N22024 001 May 12, 2009 May NEWA

>A> + 1GM;EQ 30MG BASE

N22024 002 May 12, 2009 May NEWA

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

+ LUNDBECK INC 5MG

N05378 002 Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

DESOXYN

@ LUNDBECK INC 5MG

N05378 004 Apr CAHN

@ 10MG

N05378 003 Apr CAHN

@ 15MG

N05378 005 Apr CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

>D> AB + GENPHARM 10MG

N40350 002 Mar 29, 2000 May CRLD

>A> AB 10MG

N40350 002 Mar 29, 2000 May CRLD

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

@ SOLCO HLTHCARE 500MG

N86989 001 Jan CAHN

@ 750MG

N86988 001 Jan CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP EBEWE PARENTA EQ 50MG BASE/2ML (EQ 25MG BASE/ML)

N90039 001 Mar 31, 2009 Mar NEWA

AP EQ 250MG BASE/10ML (EQ 25MG BASE/ML)

N90039 002 Mar 31, 2009 Mar NEWA

AP EQ 1GM BASE/40ML (EQ 25MG BASE/ML)

N90029 001 Mar 31, 2009 Mar NEWA

METHYCLOTHIAZIDE

TABLET; ORAL

ENDURON

ABBOTT 2.5MG

N12524 001 Mar CTEC

METHYCLOTHIAZIDE

@ SANDOZ 2.5MG

N89835 001 Aug 18, 1988 Mar DISC

@ 5MG

N89837 001 Aug 18, 1988 Mar DISC

METHYLDOPA

TABLET; ORAL

METHYLDOPA

@ SANDOZ 125MG

N71700 001 Mar 02, 1988 Mar DISC

@ 250MG

N18934 001 Jun 29, 1984 Mar DISC

@ 500MG

N18934 002 Jun 29, 1984 Mar DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

AB SANDOZ 40MG/ML

N40719 001 Jan 29, 2009 Jan NEWA

AB 40MG/ML

N40794 001 Mar 05, 2009 Feb NEWA

AB 80MG/ML

N40719 002 Jan 29, 2009 Jan NEWA

AB 80MG/ML

N40794 002 Mar 05, 2009 Feb NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA VISTAPHARM EQ 5MG BASE/5ML

N75051 001 Jan 26, 2001 Mar CMFD

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@ SANDOZ EQ 5MG BASE

N74478 001 Oct 05, 1995 Mar DISC

@ EQ 10MG BASE

N72215 001 Jan 30, 1990 Mar DISC

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

@ SOLCO HLTHCARE 50MG

N74453 001 Apr 27, 1995 Jan CAHN

@ 100MG

N74453 002 Apr 27, 1995 Jan CAHN

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

AB ALEMBIC LTD 250MG

N79067 001 Mar 13, 2009 Mar NEWA

AB 500MG

N79067 002 Mar 13, 2009 Mar NEWA

@ SANDOZ 250MG

N18740 001 Oct 22, 1982 Mar DISC

@ 500MG

N18740 002 Oct 22, 1982 Mar DISC

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

@ SANDOZ 150MG

N74450 001 May 16, 1996 Mar DISC

@ 200MG

N74450 002 May 16, 1996 Mar DISC

@ 250MG

N74450 003 May 16, 1996 Mar DISC

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+	STIEFEL LABS INC	0.25%;81.35%;15%	N21026 001	Feb 16, 2006	Jan	CAHN
---	------------------	------------------	------------	--------------	-----	------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

	CYPRESS BIOSCIENCE	12.5MG	N22256 001	Jan 14, 2009	Jan	NEWA
		25MG	N22256 002	Jan 14, 2009	Jan	NEWA
		50MG	N22256 003	Jan 14, 2009	Jan	NEWA
+		100MG	N22256 004	Jan 14, 2009	Jan	NEWA

MINOCYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

MINOCIN

>D>	@ TRIAX PHARMS LLC	EQ 100MG BASE/VIAL	N50444 001		May	CMFD
>A>	+	EQ 100MG BASE/VIAL	N50444 001		May	CMFD

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	BARR	EQ 45MG BASE	N65485 001	Mar 17, 2009	Mar	NEWA
AB		EQ 90MG BASE	N65485 002	Mar 17, 2009	Mar	NEWA
AB		EQ 135MG BASE	N65485 003	Mar 17, 2009	Mar	NEWA
AB	IMPAX LABS INC	EQ 45MG BASE	N90024 001	Feb 03, 2009	Jan	NEWA
AB		EQ 90MG BASE	N90024 002	Feb 03, 2009	Jan	NEWA
AB		EQ 135MG BASE	N90024 003	Feb 03, 2009	Jan	NEWA
	SOLODYN					
AB	MEDICIS	EQ 45MG BASE	N50808 001	May 08, 2006	Jan	CFTG
AB		EQ 90MG BASE	N50808 002	May 08, 2006	Jan	CFTG
AB	+	EQ 135MG BASE	N50808 003	May 08, 2006	Jan	CFTG

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP	GENERAMEDIX	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N78980 001	Apr 13, 2009	Mar	NEWA
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	N78980 002	Apr 13, 2009	Mar	NEWA

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACURIUM CHLORIDE

+	EBEWE PARENTA	EQ 2MG BASE/ML	N78562 001	Apr 30, 2009	Apr	NEWA
---	---------------	----------------	------------	--------------	-----	------

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

+	ACTAVIS ELIZABETH	10MG	N20616 008	Apr 20, 2007	Feb	CRLD
+		80MG	N20616 006	Oct 27, 2006	Feb	CRLD

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

@	AB GENERICS	15MG	N74862 001	Jul 07, 1998	Apr	DISC
@		30MG	N74862 002	Jul 07, 1998	Apr	DISC
@		60MG	N74862 003	Jul 07, 1998	Apr	DISC
@		100MG	N74769 001	Jul 02, 1998	Apr	DISC

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

@ AB GENERICS 200MG

N74769 002 Jul 02, 1998 Apr DISC

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

AB ACCORD HLTHCARE INC 250MG

N90253 001 May 04, 2009 Apr NEWA

AB APOTEX CORP 250MG

N90419 001 Apr 22, 2009 Apr NEWA

AB MYLAN 250MG

N65520 001 May 04, 2009 Apr NEWA

AB TEVA PHARMS 250MG

N65491 001 May 06, 2009 Apr NEWA

AB ZYDUS PHARMS USA INC 250MG

N65433 001 May 04, 2009 Apr NEWA

TABLET; ORAL

MYCOPHENOLATE MOFETIL

AB ACCORD HLTHCARE 500MG

N65416 001 May 04, 2009 Apr NEWA

AB APOTEX 500MG

N90499 001 Apr 22, 2009 Apr NEWA

AB MYLAN 500MG

N65521 001 May 04, 2009 Apr NEWA

AB TEVA PHARMS 500MG

N65457 001 May 04, 2009 Apr NEWA

AB ZYDUS PHARMS USA INC 500MG

N65477 001 May 04, 2009 Apr NEWA

NABUMETONE

TABLET; ORAL

NABUMETONE

AB ACTAVIS ELIZABETH 500MG

N79093 001 Feb 27, 2009 Feb NEWA

AB 750MG

N79093 002 Feb 27, 2009 Feb NEWA

@ SANDOZ 500MG

N75590 001 Feb 25, 2002 Mar DISC

@ 750MG

N75590 002 Feb 25, 2002 Mar DISC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

>D> + MALLINCKRODT 100MG

N76264 003 Mar 22, 2002 May CRLD

>A> 100MG

N76264 003 Mar 22, 2002 May CRLD

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

+ STAT TRADE EQ 375MG BASE

N20353 001 Jan 05, 1996 Mar CTEC

+ EQ 500MG BASE

N20353 002 Jan 05, 1996 Mar CTEC

NAPROXEN SODIUM

@ WATSON LABS FLORIDA EQ 375MG BASE

N75416 002 Apr 23, 2003 Mar DISC

@ EQ 500MG BASE

N75416 001 Aug 27, 2002 Mar DISC

NIFEDIPINE

CAPSULE; ORAL

PROCARDIA

AB + PFIZER 10MG

N18482 001 Apr CRLD

@ 20MG

N18482 002 Jul 24, 1986 Apr DISC

NIMODIPINE

CAPSULE; ORAL

NIMODIPINE

AB + BARR 30MG

N77811 001 May 02, 2007 Mar CRLD

NIMOTOP

@ BAYER PHARMS 30MG

N18869 001 Dec 28, 1988 Feb DISC

NITISINONE

CAPSULE; ORAL

ORFADIN

RARE DIS	2MG	N21232 001	Jan 18, 2002	Mar	CAHN
	5MG	N21232 002	Jan 18, 2002	Mar	CAHN
+	10MG	N21232 003	Jan 18, 2002	Mar	CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

@ SANDOZ	25MG	N74336 001	Jan 25, 1995	Mar	DISC
@	50MG	N74336 002	Jan 25, 1995	Mar	DISC
@	100MG	N74336 003	Jan 25, 1995	Mar	DISC

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

AT	FDC LTD	0.3%	N78559 001	Feb 25, 2009	Feb	NEWA
----	---------	------	------------	--------------	-----	------

TABLET; ORAL

FLOXIN

@ ORTHO MCNEIL JANSSEN	200MG	N19735 001	Dec 28, 1990	Mar	DISC
@	300MG	N19735 002	Dec 28, 1990	Mar	DISC
@	400MG	N19735 003	Dec 28, 1990	Mar	DISC

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+	ALAVEN PHARM	250MG	N19715 001	Jul 31, 1990	Apr	CAHN
---	--------------	-------	------------	--------------	-----	------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB	DR REDDYS LABS	40MG	N78490 001	Apr 17, 2009	Mar	NEWA
AB	DR REDDYS LABS LTD	10MG	N78693 001	Mar 16, 2009	Mar	NEWA
AB		20MG	N78693 002	Mar 16, 2009	Mar	NEWA
AB	KREMERS URBAN DEV	40MG	N75410 003	Jan 23, 2009	Jan	NEWA

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE MAGNESIUM

>A>	DR REDDYS LABS LTD	20MG	N78878 001	Jun 05, 2009	May	NEWA
-----	--------------------	------	------------	--------------	-----	------

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

AP	BEDFORD LABS	EQ 0.64MG BASE/ML	N78291 001	Apr 13, 2009	Mar	NEWA
----	--------------	-------------------	------------	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

@ WATSON LABS	EQ 250MG BASE/VIAL	N62856 001	Oct 26, 1988	Apr	DISC
@	EQ 500MG BASE/VIAL	N62856 002	Oct 26, 1988	Apr	DISC
@	EQ 1GM BASE/VIAL	N62856 003	Oct 26, 1988	Apr	DISC
@	EQ 2GM BASE/VIAL	N62856 004	Oct 26, 1988	Apr	DISC
@	EQ 4GM BASE/VIAL	N62856 005	Oct 26, 1988	Apr	DISC

OXAPROZIN

TABLET; ORAL

OXAPROZIN

@ SANDOZ	600MG	N75850 001	Apr 27, 2001	Mar	DISC
----------	-------	------------	--------------	-----	------

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

+ WATSON LABS	10%(100MG/PACKET)	N22204 001	Jan 27, 2009	Mar	CTNA
---------------	-------------------	------------	--------------	-----	------

OXYBUTYNIN CHLORIDE

+ WATSON LABS	10%(100MG/PACKET)	N22204 001	Jan 27, 2009	Jan	NEWA
---------------	-------------------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB	OSMOTICA PHARM	5MG	N78503 001	Feb 04, 2009	Jan	NEWA
AB		10MG	N78503 002	Feb 04, 2009	Jan	NEWA
AB		15MG	N78503 003	Feb 04, 2009	Jan	NEWA

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB	SUN PHARM INDS INC	5MG	N90659 001	Apr 10, 2009	Mar	NEWA
AB		15MG	N90659 002	Apr 10, 2009	Mar	NEWA
AB		30MG	N90659 003	Apr 10, 2009	Mar	NEWA
AB	VINTAGE PHARMS	5MG	N77712 003	Mar 02, 2009	Mar	NEWA

ROXICODONE

>A> AB	XANODYNE PHARMS	5MG	N21011 003	May 15, 2009	May	NEWA
--------	-----------------	-----	------------	--------------	-----	------

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	GENERAMEDIX	30MG/VIAL	N78300 001	Mar 10, 2009	Feb	NEWA
AP		90MG/VIAL	N78300 002	Mar 10, 2009	Feb	NEWA

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE; ORAL

CREON

SOLVAY

	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N20725 001	Apr 30, 2009	Apr	NEWA
	60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N20725 002	Apr 30, 2009	Apr	NEWA
+	120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N20725 003	Apr 30, 2009	Apr	NEWA

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

@ HOSPIRA

2MG/ML

N72321 001	Jan 19, 1989	Apr	DISC
------------	--------------	-----	------

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	KUDCO IRELAND	EQ 20MG BASE	N78281 001	Mar 17, 2009	Mar	NEWA
AB		EQ 40MG BASE	N78281 002	Mar 17, 2009	Mar	NEWA

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN-VK

AA	+	TEVA	EQ 250MG BASE/5ML	N60456 002	Apr	CRLD
		VEETIDS				
	@	APOTHECON	EQ 125MG BASE/5ML	N61410 001	Mar	DISC
	@		EQ 250MG BASE/5ML	N61410 002	Mar	DISC

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

>D>		APP PHARMS	600MG/VIAL	N19887 002	Mar 22, 1996	May	DISC
>A>		@	600MG/VIAL	N19887 002	Mar 22, 1996	May	DISC

PHENDIMETRAZINE TARTRATE

>D>		CAPSULE; ORAL					
>D>		PHENDIMETRAZINE TARTRATE					
>D>	+	SANDOZ	35MG	N85695 001		May	DISC
>A>	@		35MG	N85695 001		May	DISC

PHENYTOIN

SUSPENSION; ORAL

PHENYTOIN

AB		WOCKHARDT EU	125MG/5ML	N40420 001	Apr 19, 2002	Apr	CAHN
----	--	--------------	-----------	------------	--------------	-----	------

PHENYTOIN SODIUM

CAPSULE; ORAL

PROMPT PHENYTOIN SODIUM

	@	IVAX PHARMS	100MG PROMPT	N80259 001		Jan	DISC
--	---	-------------	--------------	------------	--	-----	------

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB		LANNETT	7.5MG	N77220 002	May 06, 2009	Apr	NEWA
----	--	---------	-------	------------	--------------	-----	------

PINDOLOL

TABLET; ORAL

PINDOLOL

	@	SANDOZ	5MG	N73608 001	Mar 29, 1993	Mar	DISC
--	---	--------	-----	------------	--------------	-----	------

	@		10MG	N73609 001	Mar 29, 1993	Mar	DISC
--	---	--	------	------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

AA		GAVIS PHARMS	17GM/SCOOPFUL	N77736 001	May 26, 2006	Jan	CAHN
	@	TEVA PHARMS	17GM/SCOOPFUL	N77445 001	May 04, 2006	Jan	DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

PEG-3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

>A>	AA	NOVEL LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N90019 001	May 27, 2009	May	NEWA
-----	----	----------------	--	------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

GOLYTELY

>D>	AA	+	BRAINTREE	227.1GM/PACKET;2.82GM/PACKET;6.36 GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N19011 002	Jun 02, 1992	May	CTEC
>A>		+		227.1GM/PACKET;2.82GM/PACKET;6.36 GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N19011 002	Jun 02, 1992	May	CTEC
>D>		+		236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	N19011 001	Jul 13, 1984	May	CFTG
>A>	AA	+		236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	N19011 001	Jul 13, 1984	May	CFTG
		+		236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	N19011 001	Jul 13, 1984	Mar	CTEC
>A>			PEG 3350 AND ELECTROLYTES					
>A>	AA		NOVEL LABS INC	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	N90231 001	Jun 01, 2009	May	NEWA
>A>	AA			240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N90186 001	Jun 01, 2009	May	NEWA

FOR SUSPENSION; ORAL

CO-LAV

@ BOCA PHARMA

240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT

N73428 001 Jan 28, 1992 Mar DISC

GO-EVAC

@ BOCA PHARMA

236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT

N73433 001 Apr 28, 1992 Mar DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K

@ KV PHARM

8MEQ

N18238 001

Feb DISC

MICRO-K 10

@ KV PHARM

10MEQ

N18238 002 May 14, 1984 Feb DISC

POTASSIUM CHLORIDE

@ KV PHARM

10MEQ

N70980 001 Feb 17, 1987 Feb DISC

WATSON LABS FLORIDA

8MEQ

N77419 001 Jun 02, 2008 Feb CTEC

+

10MEQ

N77419 002 Jun 02, 2008 Feb CRLD

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

@ HOSPIRA

1.5MEQ/ML

N83345 001

Apr DISC

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

>D>	AB	+	WATSON LABS FLORIDA	10MEQ	N75604 001	Apr 10, 2002	May	CRLD
>A>	AB			10MEQ	N75604 001	Apr 10, 2002	May	CRLD
	AB	+		10MEQ	N75604 001	Apr 10, 2002	Jan	CRLD

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

@ SANDOZ

EQ 1MG BASE

N72576 001 May 16, 1989 Mar DISC

@

EQ 2MG BASE

N72577 001 May 16, 1989 Mar DISC

@

EQ 5MG BASE

N72578 001 May 16, 1989 Mar DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

	AA		AMNEAL PHARMS	EQ 15MG BASE/5ML	N78345 001	Mar 10, 2009	Feb	NEWA
>A>	AA		VINTAGE	EQ 15MG BASE/5ML	N79010 001	May 26, 2009	May	NEWA

SOLUTION/DROPS; OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

@ BAUSCH AND LOMB

EQ 0.11% PHOSPHATE

N40065 001 Jul 29, 1994 Apr DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

@ SANDOZ

10MG

N89983 001 Jan 12, 1989 Mar DISC

@

50MG

N89984 001 Jan 12, 1989 Mar DISC

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST PLAIN DENTAL

+ DENTSPLY PHARM 4%

N21382 001 Apr CTNA

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA SUN PHARM INDS INC 6.25MG/5ML

N40891 001 Mar 13, 2009 Mar NEWA

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

>A> AB SANDOZ 12.5MG

N84176 002 May 22, 2009 May NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DOLENE

AA HERITAGE PHARMS INC 65MG

N80530 001 Mar CMFD

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB UPSHER SMITH 60MG

N78311 001 Mar 06, 2009 Feb NEWA

AB 80MG

N78311 002 Mar 06, 2009 Feb NEWA

AB 120MG

N78311 003 Mar 06, 2009 Feb NEWA

AB 160MG

N78311 004 Mar 06, 2009 Feb NEWA

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

@ SANDOZ 10MG

N70663 001 Jun 13, 1986 Mar DISC

@ 20MG

N70664 001 Jun 13, 1986 Mar DISC

@ 40MG

N70665 001 Jun 13, 1986 Mar DISC

@ 60MG

N70666 001 Oct 10, 1986 Mar DISC

@ 80MG

N70667 001 Jun 13, 1986 Mar DISC

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

CORPHED

@ SANDOZ 60MG; 2.5MG

N88602 001 Apr 11, 1985 Mar DISC

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

+ SANDOZ 60MG; 2.5MG

N88193 001 May 17, 1983 Mar CTEC

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

AB RANBAXY 5MG

N78849 001 Mar 06, 2009 Feb NEWA

AB 10MG

N78849 002 Mar 06, 2009 Feb NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

@ BEDFORD

EQ 25MG BASE/ML

N74764 001 Nov 19, 2004 Apr DISC

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 15MG BASE/ML	N78312 001	Sep 02, 2008	Feb	CTNA
>A>	AA	DR REDDYS LABS LTD	EQ 15MG BASE/ML	N90102 001	May 26, 2009	May NEWA
>A>	AA	WOCKHARDT	EQ 15MG BASE/ML	N79211 001	May 26, 2009	May NEWA
AA		EQ 15MG BASE/ML	N79212 001	Feb 23, 2009	Feb	NEWA

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

>D>	PROCTER AND GAMBLE	75MG	N20835 004	Apr 16, 2007	May	DISC
>A>	@	75MG	N20835 004	Apr 16, 2007	May	DISC

RISPERIDONE

SOLUTION; ORAL

RISPERDAL

AA	+ ORTHO MCNEIL JANSSEN	1MG/ML	N20588 001	Jun 10, 1996	Jan	CFTG
----	------------------------	--------	------------	--------------	-----	------

RISPERIDONE

AA	TEVA	1MG/ML	N76440 001	Jan 30, 2009	Jan	NEWA
----	------	--------	------------	--------------	-----	------

TABLET; ORAL

RISPERIDONE

AB	CADISTA PHARMS	0.25MG	N78828 001	Mar 23, 2009	Mar	NEWA
AB		0.5MG	N78828 002	Mar 23, 2009	Mar	NEWA
AB		1MG	N78828 003	Mar 23, 2009	Mar	NEWA
AB		2MG	N78828 004	Mar 23, 2009	Mar	NEWA
AB		3MG	N78828 005	Mar 23, 2009	Mar	NEWA
AB		4MG	N78828 006	Mar 23, 2009	Mar	NEWA
>A>	AB	WEST WARD PHARMS	0.25MG	N78740 001	May 29, 2009	May NEWA
>A>	AB	0.5MG	N78740 002	May 29, 2009	May	NEWA
>A>	AB	1MG	N78740 003	May 29, 2009	May	NEWA
>A>	AB	2MG	N78740 004	May 29, 2009	May	NEWA
>A>	AB	3MG	N78740 005	May 29, 2009	May	NEWA
>A>	AB	4MG	N78740 006	May 29, 2009	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

AB	ORTHOMCNEIL JANSSEN	0.5MG	N21444 001	Apr 02, 2003	Feb	CFTG
AB		2MG	N21444 003	Apr 02, 2003	Feb	CFTG
AB		3MG	N21444 004	Dec 23, 2004	Apr	CFTG
AB		4MG	N21444 005	Dec 23, 2004	Apr	CFTG

RISPERIDONE

AB	DR REDDYS LABS LTD	0.5MG	N77328 001	Feb 24, 2009	Feb	NEWA
AB		2MG	N77328 003	Feb 24, 2009	Feb	NEWA
	KALI LABS	0.25MG	N77494 001	Apr 30, 2009	Apr	NEWA
AB		0.5MG	N77494 002	Apr 30, 2009	Apr	NEWA
AB		2MG	N77494 004	Apr 30, 2009	Apr	NEWA
AB		3MG	N77494 005	Apr 30, 2009	Apr	NEWA
AB		4MG	N77494 006	Apr 30, 2009	Apr	NEWA
AB	ZYDUS PHARMS USA	0.5MG	N78516 001	May 01, 2009	Apr	NEWA
AB		2MG	N78516 003	May 01, 2009	Apr	NEWA

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HYDROCHLORIDE

@	HOSPIRA	10MG/ML	N71618 001	Feb 28, 1991	Apr	DISC
@		15MG/ML	N71619 001	Feb 28, 1991	Apr	DISC
	RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER					
@	HOSPIRA	30MG/100ML	N71438 001	Jan 22, 1991	Apr	DISC

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	HUAHAI US INC	EQ 0.25MG BASE	N78110 001	May 05, 2008	Apr	CAHN
AB		EQ 0.5MG BASE	N78110 002	May 05, 2008	Apr	CAHN
AB		EQ 1MG BASE	N78110 003	May 05, 2008	Apr	CAHN
AB		EQ 2MG BASE	N78110 004	May 05, 2008	Apr	CAHN
AB		EQ 3MG BASE	N78110 005	May 05, 2008	Apr	CAHN
AB		EQ 4MG BASE	N78110 006	May 05, 2008	Apr	CAHN
>A>	AB	ZYDUS PHARMS USA INC	EQ 0.25MG BASE	N90411 001	Jun 01, 2009	May NEWA
>A>	AB		EQ 0.5MG BASE	N90411 002	Jun 01, 2009	May NEWA
>A>	AB		EQ 1MG BASE	N90411 003	Jun 01, 2009	May NEWA
>A>	AB		EQ 2MG BASE	N90411 004	Jun 01, 2009	May NEWA
>A>	AB		EQ 3MG BASE	N90411 005	Jun 01, 2009	May NEWA
>A>	AB		EQ 4MG BASE	N90411 006	Jun 01, 2009	May NEWA
>A>	AB		EQ 5MG BASE	N90411 007	Jun 01, 2009	May NEWA

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

	SMITHKLINE BEECHAM	EQ 6MG BASE	N22008 006	Apr 10, 2009	Apr	NEWA
--	--------------------	-------------	------------	--------------	-----	------

SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

>D>	+	CYTOGEN	50mCi/ML	N20570 001	Mar 28, 1997	May CAHN
>A>	+	EUSA PHARMA USA	50mCi/ML	N20570 001	Mar 28, 1997	May CAHN

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

@	ENDO PHARMS	5MG	N74565 001	Aug 02, 1996	Apr	DISC
@	SIEGFRIED	5MG	N74672 001	Apr 01, 1997	Apr	DISC

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB	AUSTARPHARMA LLC	EQ 25MG BASE	N78677 001	Mar 04, 2009	Feb	NEWA
AB		EQ 50MG BASE	N78677 002	Mar 04, 2009	Feb	NEWA
AB		EQ 100MG BASE	N78677 003	Mar 04, 2009	Feb	NEWA

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB	LUPIN	5MG	N78103 005	Apr 14, 2009	Mar	NEWA
----	-------	-----	------------	--------------	-----	------

>D>	<u>SODIUM PHOSPHATE, P-32</u>									
>D>	SOLUTION; INJECTION, ORAL									
>D>	SODIUM PHOSPHATE P 32									
>D>	MALLINCKRODT	0.67mCi/ML	N11777 001				May	DISC		
>A>	@	0.67mCi/ML	N11777 001				May	DISC		
<u>SODIUM POLYSTYRENE SULFONATE</u>										
POWDER; ORAL, RECTAL										
KALEXATE										
AA	KVK TECH	454GM/BOT	N40905 001	Mar 30, 2009	Mar	NEWA				
<u>SOMATROPIN RECOMBINANT</u>										
INJECTABLE; INJECTION										
NORDITROPIN NORDIFLEX										
	NOVO NORDISK INC	30MG/3ML	N21148 007	Mar 10, 2009	Mar	NEWA				
<u>STANOSZOLOL</u>										
TABLET; ORAL										
WINSTROL										
	@ LUNDBECK INC	2MG	N12885 001	May 14, 1984	Mar	CAHN				
<u>STAVUDINE</u>										
FOR SOLUTION; ORAL										
STAVUDINE										
AA	CIPLA LTD	1MG/ML	N78030 001	Mar 20, 2009	Mar	NEWA				
<u>SUCCIMER</u>										
CAPSULE; ORAL										
CHEMET										
+	LUNDBECK INC	100MG	N19998 002	Jan 30, 1991	Mar	CAHN				
<u>SULFACETAMIDE SODIUM</u>										
LOTION; TOPICAL										
SULFACETAMIDE SODIUM										
AB	PERRIGO CO TENNESSEE	10%	N78649 001	Mar 23, 2009	Mar	NEWA				
>A>	AB	TARO	10%	N78668 001	May 20, 2009	May	NEWA			
SOLUTION/DROPS; OPHTHALMIC										
SULF-10										
	@ NOVARTIS	10%	N80025 001				Apr	DISC		
SULFACETAMIDE SODIUM										
	@ ALCON	30%	N89068 001	May 05, 1987	Apr	DISC				
<u>SULFAMETHOXAZOLE; TRIMETHOPRIM</u>										
TABLET; ORAL										
SULFAMETHOPRIM										
AB	PAR PHARM	400MG;80MG	N70022 001	Feb 15, 1985	Mar	CMFD				
SULFAMETHOPRIM-DS										
AB	PAR PHARM	800MG;160MG	N70032 001	Feb 15, 1985	Mar	CMFD				
SULFAMETHOXAZOLE AND TRIMETHOPRIM										
	@ SANDOZ	800MG;160MG	N70890 001	Nov 13, 1986	Mar	DISC				
<u>SULINDAC</u>										
TABLET; ORAL										
SULINDAC										
	@ SANDOZ	150MG	N72712 001	Aug 30, 1991	Mar	DISC				

TABLET; ORAL

SULINDAC

@ SANDOZ

200MG

N72713 001 Aug 30, 1991 Mar DISC

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX

AP	+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N20080 001	Dec 28, 1992	Jan	CFTG
----	---	-----------------	-------------------------------------	------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

AP		APP PHARMS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N79242 001	Mar 02, 2009	Feb	NEWA
----	--	------------	-------------------------------------	------------	--------------	-----	------

AP		BEDFORD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N79123 001	Feb 06, 2009	Jan	NEWA
----	--	---------	-------------------------------------	------------	--------------	-----	------

AP		SANDOZ	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N78067 002	Feb 06, 2009	Jan	NEWA
----	--	--------	------------------------------------	------------	--------------	-----	------

AP			EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N78067 001	Feb 06, 2009	Jan	NEWA
----	--	--	-------------------------------------	------------	--------------	-----	------

AP		TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N78318 001	Feb 06, 2009	Jan	NEWA
----	--	-----------------	------------------------------------	------------	--------------	-----	------

AP			EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N78318 002	Feb 06, 2009	Jan	NEWA
----	--	--	-------------------------------------	------------	--------------	-----	------

AP			EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N77907 001	Feb 06, 2009	Jan	NEWA
----	--	--	-------------------------------------	------------	--------------	-----	------

AP		WOCKHARDT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N78593 001	Feb 06, 2009	Jan	NEWA
----	--	-----------	-------------------------------------	------------	--------------	-----	------

TABLET; ORAL

IMITREX

AB		GLAXOSMITHKLINE	EQ 25MG BASE	N20132 002	Jun 01, 1995	Jan	CFTG
----	--	-----------------	--------------	------------	--------------	-----	------

AB			EQ 50MG BASE	N20132 003	Jun 01, 1995	Jan	CFTG
----	--	--	--------------	------------	--------------	-----	------

AB	+		EQ 100MG BASE	N20132 001	Jun 01, 1995	Jan	CFTG
----	---	--	---------------	------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

AB		RANBAXY	EQ 100MG BASE	N76572 001	Feb 09, 2009	Jan	NEWA
----	--	---------	---------------	------------	--------------	-----	------

AB		TEVA	EQ 25MG BASE	N76840 001	Feb 09, 2009	Jan	NEWA
----	--	------	--------------	------------	--------------	-----	------

AB			EQ 50MG BASE	N76840 002	Feb 09, 2009	Jan	NEWA
----	--	--	--------------	------------	--------------	-----	------

AB			EQ 100MG BASE	N76840 003	Feb 09, 2009	Jan	NEWA
----	--	--	---------------	------------	--------------	-----	------

SUNITINIB MALATE

CAPSULE; ORAL

SUTENT

CPPI CV

EQ 37.5MG BASE

N21938 004 Mar 31, 2009 Mar NEWA

TADALAFIL

TABLET; ORAL

ADCIRCA

>A>

>A>

+ ELI LILLY CO 20MG

N22332 001 May 22, 2009 May NEWA

TAMOXIFEN CITRATE

TABLET; ORAL

TAMOXIFEN CITRATE

@ ROXANE

EQ 10MG BASE

N76027 001 Feb 20, 2003 Mar DISC

@

EQ 20MG BASE

N76027 002 Feb 20, 2003 Mar DISC

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION

NEUROLITE

LANTHEUS MEDCL

N/A

N20256 001 Nov 23, 1994 Apr CPOT

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

+	DRAXIMAGE	N/A	N18035 001		Apr	CTEC
	DRAXIMAGE MDP-25					
	@ DRAXIMAGE	N/A	N18035 002	Feb 27, 2004	Apr	DISC
	TECHNETIUM TC 99M MPI MDP					
	@ GE HEALTHCARE	N/A	N18141 002	Jun 12, 1989	Apr	DISC
	@	N/A	N18141 001		Apr	DISC

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M SESTAMIBI

AP	CARDINAL HEALTH 414	N/A	N78809 001	Apr 28, 2009	Apr	NEWA
AP	DRAXIMAGE	N/A	N78806 001	Apr 29, 2009	Apr	NEWA

TELBIVUDINE

SOLUTION; ORAL

TYZEKA

+	NOVARTIS	100MG/5ML	N22154 001	Apr 28, 2009	Apr	NEWA
---	----------	-----------	------------	--------------	-----	------

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

@	NOVEL LABS INC	30MG	N71457 001	Apr 21, 1987	Mar	CAHN
---	----------------	------	------------	--------------	-----	------

TEMOZOLOMIDE

POWDER; INTRAVENOUS

TEMODAR

+	SCHERING	100MG/VIAL	N22277 001	Feb 27, 2009	Feb	NEWA
---	----------	------------	------------	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

>D>	@	IVAX PHARMS	EQ 1MG BASE	N75614 002	Jan 30, 2001	May	CMFD
>A>	AB		EQ 1MG BASE	N75614 002	Jan 30, 2001	May	CMFD
>D>	@		EQ 2MG BASE	N75614 001	Jan 30, 2001	May	CMFD
>A>	AB		EQ 2MG BASE	N75614 001	Jan 30, 2001	May	CMFD
>D>	@		EQ 5MG BASE	N75614 003	Jan 30, 2001	May	CMFD
>A>	AB		EQ 5MG BASE	N75614 003	Jan 30, 2001	May	CMFD
>D>	@		EQ 10MG BASE	N75614 004	Jan 30, 2001	May	CMFD
>A>	AB		EQ 10MG BASE	N75614 004	Jan 30, 2001	May	CMFD

TABLET; ORAL

HYTRIN

ABBOTT

+		EQ 1MG BASE	N19057 001	Aug 07, 1987	Mar	CTEC
		EQ 2MG BASE	N19057 002	Aug 07, 1987	Mar	CTEC
		EQ 5MG BASE	N19057 003	Aug 07, 1987	Mar	CTEC
		EQ 10MG BASE	N19057 004	Aug 07, 1987	Mar	CTEC

TERAZOSIN HYDROCHLORIDE

@	SANDOZ	EQ 1MG BASE	N74315 001	Dec 31, 1998	Mar	DISC
@		EQ 2MG BASE	N74315 002	Dec 31, 1998	Mar	DISC
@		EQ 5MG BASE	N74315 003	Dec 31, 1998	Mar	DISC
@		EQ 10MG BASE	N74315 004	Dec 31, 1998	Mar	DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

>A>	AP	HIKMA FARMACEUTICA	1MG/ML	N78630 001	May 20, 2009	May	NEWA
-----	----	--------------------	--------	------------	--------------	-----	------

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

LILLY

0.6MG/2.4ML (0.25MG/ML)

N21318 002 Jun 25, 2008 Feb NEWA

+

0.75MG/3ML (0.25MG/ML)

N21318 001 Nov 26, 2002 Feb CPOT

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

UNIMED PHARMS

1% (2.5GM/PACKET)

N21015 001 Feb 28, 2000 Mar CTEC

BX

+

1% (5GM/PACKET)

N21015 002 Feb 28, 2000 Mar CTEC

TESTOSTERONE

@ WATSON LABS

1% (5GM/PACKET)

N76737 002 Jan 27, 2006 Mar DISC

@

1% (2.5GM/PACKET)

N76737 001 Jan 27, 2006 Mar DISC

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTYL

AO

+

ENDO PHARM

200MG/ML

N09165 003

Apr CAHN

@

200MG/ML

N09165 001

Apr CAHN

AO

+

ENDO PHARMS

200MG/ML

N09165 003

Mar CAHN

@

200MG/ML

N09165 001

Mar CAHN

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

+

NYCOMED US

0.05%

N86576 002

Apr CAHN

0.1%

N86576 001

Apr CAHN

SPRAY; NASAL

TYZINE

+

NYCOMED US

0.1%

N86576 003

Apr CAHN

THEOPHYLLINE

ELIXIR; ORAL

THEOPHYLLINE

AA

PRECISION DOSE

80MG/15ML

N85863 001

Apr CAHN

SOLUTION; ORAL

THEOPHYLLINE

@ ROXANE

80MG/15ML

N87449 001 Sep 15, 1983 Mar DISC

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOPTIC

AT

+

ATON

EQ 0.25% BASE

N18086 001

Feb CAHN

AT

+

EQ 0.5% BASE

N18086 002

Feb CAHN

TIMOPTIC IN OCULOSE

+

ATON

EQ 0.25% BASE

N19463 001 Nov 05, 1986 Feb CAHN

+

EQ 0.5% BASE

N19463 002 Nov 05, 1986 Feb CAHN

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOPTIC-XE

AB	+	ATON	EQ 0.25% BASE	N20330 001	Nov 04, 1993	Feb	CAHN
AB	+		EQ 0.5% BASE	N20330 002	Nov 04, 1993	Feb	CAHN

TABLET; ORAL

TIMOLOL MALEATE

		MYLAN	5MG	N72666 001	Jun 08, 1990	Mar	CTEC
			10MG	N72667 001	Jun 08, 1990	Mar	CTEC
	+		20MG	N72668 001	Jun 08, 1990	Mar	CTEC
		@ SANDOZ	5MG	N72550 001	Apr 13, 1989	Mar	DISC
		@	10MG	N72551 001	Apr 13, 1989	Mar	DISC
		@	20MG	N72552 001	Apr 13, 1989	Mar	DISC

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

		IVAX PHARMS	100MG	N18894 001	Nov 02, 1984	Mar	CTEC
		@ SANDOZ	100MG	N71633 001	Dec 09, 1987	Mar	DISC
		@	250MG	N70289 001	Mar 13, 1986	Mar	DISC
		@	500MG	N70290 001	Mar 13, 1986	Mar	DISC

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

		@ SANDOZ	500MG	N86574 001		Mar	DISC
--	--	----------	-------	------------	--	-----	------

TOLMETIN SODIUM

TABLET; ORAL

TOLMETIN SODIUM

		@ SANDOZ	EQ 200MG BASE	N73588 001	Jul 31, 1992	Mar	DISC
		@	EQ 600MG BASE	N74002 001	Sep 27, 1993	Mar	DISC

>A> TOLVAPTAN

>A> TABLET; ORAL

>A> SAMSCA

>A>		OTSUKA AMERICA PHARM	15MG	N22275 001	May 19, 2009	May	NEWA
>A>	+		30MG	N22275 002	May 19, 2009	May	NEWA
>A>		@	60MG	N22275 003	May 19, 2009	May	DISC

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX

AB		ORTHO MCNEIL JANSSEN	15MG	N20844 001	Oct 26, 1998	Mar	CFTG
AB	+		25MG	N20844 002	Oct 26, 1998	Mar	CFTG

TOPIRAMATE

AB		BARR	15MG	N76448 001	Apr 15, 2009	Mar	NEWA
AB			25MG	N76448 002	Apr 15, 2009	Mar	NEWA
AB		COBALT LABS INC	15MG	N77868 001	Apr 15, 2009	Mar	NEWA
AB			25MG	N77868 002	Apr 15, 2009	Mar	NEWA
AB		TEVA	15MG	N76575 001	Apr 17, 2009	Mar	NEWA
AB			25MG	N76575 002	Apr 17, 2009	Mar	NEWA

TABLET; ORAL

TOPAMAX

AB	+	ORTHO MCNEIL JANSSEN	25MG	N20505 004	Dec 24, 1996	Mar	CFTG
AB			50MG	N20505 005	Dec 24, 1996	Mar	CFTG
AB			100MG	N20505 001	Dec 24, 1996	Mar	CFTG

TABLET; ORAL

TOPAMAX						
AB	ORTHO MCNEIL JANSSEN	200MG	N20505 002	Dec 24, 1996	Mar	CFTG
TOPIRAMATE						
AB	APOTEX INC	25MG	N77733 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N77733 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N77733 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N77733 004	Mar 27, 2009	Mar	NEWA
AB	AUROBINDO PHARMA	25MG	N78462 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N78462 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N78462 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N78462 004	Mar 27, 2009	Mar	NEWA
AB	BARR	25MG	N76315 001	Mar 27, 2009	Mar	NEWA
AB		100MG	N76315 002	Mar 27, 2009	Mar	NEWA
AB		200MG	N76315 003	Mar 27, 2009	Mar	NEWA
AB	CIPLA LTD	25MG	N76343 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76343 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76343 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76343 004	Mar 27, 2009	Mar	NEWA
AB	COBALT LABS INC	25MG	N77643 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N77643 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N77643 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N77643 004	Mar 27, 2009	Mar	NEWA
AB	GLENMARK GENERICS	25MG	N77627 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N77627 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N77627 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N77627 004	Mar 27, 2009	Mar	NEWA
AB	INVAGEN PHARMS	25MG	N79162 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N79162 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N79162 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N79162 004	Mar 27, 2009	Mar	NEWA
AB	MYLAN	25MG	N76314 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76314 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76314 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76314 004	Mar 27, 2009	Mar	NEWA
AB	PAR PHARM	25MG	N76311 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76311 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76311 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76311 004	Mar 27, 2009	Mar	NEWA
AB	PLIVA HRVATSKA DOO	25MG	N77905 001	Mar 30, 2009	Mar	NEWA
AB		50MG	N77905 002	Mar 30, 2009	Mar	NEWA
AB		100MG	N77905 003	Mar 30, 2009	Mar	NEWA
AB		200MG	N77905 004	Mar 30, 2009	Mar	NEWA
AB	RANBAXY	25MG	N76327 001	Mar 27, 2009	Mar	NEWA
AB		100MG	N76327 002	Mar 27, 2009	Mar	NEWA
AB		200MG	N76327 003	Mar 27, 2009	Mar	NEWA
AB	ROXANE	25MG	N76306 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76306 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76306 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76306 004	Mar 27, 2009	Mar	NEWA
AB	SUN PHARM INDS LTD	25MG	N90278 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N90278 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N90278 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N90278 004	Mar 27, 2009	Mar	NEWA
AB	TEVA	25MG	N76317 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76317 002	Mar 27, 2009	Mar	NEWA

TABLET; ORAL

TOPIRAMATE

AB	TEVA	100MG	N76317 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76317 004	Mar 27, 2009	Mar	NEWA
AB	TORRENT PHARMS	25MG	N79153 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N79153 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N79153 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N79153 004	Mar 27, 2009	Mar	NEWA
AB	UNICHEM	25MG	N90162 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N90162 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N90162 003	Mar 27, 2009	Mar	NEWA
AB	ZYDUS PHARMS USA INC	25MG	N78235 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N78235 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N78235 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N78235 004	Mar 27, 2009	Mar	NEWA

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB	HETERO DRUGS	5MG	N79234 001	Jan 27, 2009	Jan	NEWA
AB		10MG	N79234 002	Jan 27, 2009	Jan	NEWA
AB		20MG	N79234 003	Jan 27, 2009	Jan	NEWA
AB		100MG	N79234 004	Jan 27, 2009	Jan	NEWA

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

BC	+ PURDUE PHARMA	100MG	N21745 001	Dec 30, 2008	Mar	CAHN
BC		200MG	N21745 002	Dec 30, 2008	Mar	CAHN
BC		300MG	N21745 003	Dec 30, 2008	Mar	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

TRAMADOL HYDROCHLORIDE

@ ETHYPHARM NORTH

50MG

N21693 001 May 05, 2005 Mar CAHN

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB	ALVOGEN	50MG	N71636 001	Apr 18, 1988	Feb	CAHN
AB		100MG	N71514 001	Apr 18, 1988	Feb	CAHN
>D>	APOTEX INC	300MG	N71196 003	Apr 26, 1999	May	CTEC
>A>	AB	300MG	N71196 003	Apr 26, 1999	May	CTEC
>A>	MATRIX LABS LTD	50MG	N90514 001	Jun 02, 2009	May	NEWA
>A>	AB	100MG	N90514 002	Jun 02, 2009	May	NEWA
>A>	AB	150MG	N90514 003	Jun 02, 2009	May	NEWA
>A>	AB	300MG	N90514 004	Jun 02, 2009	May	NEWA
	@ SANDOZ	50MG	N72484 001	Apr 30, 1990	Mar	DISC
	@	100MG	N72483 001	Apr 30, 1990	Mar	DISC

TRIAMCINOLONE ACETONIDE

INJECTABLE; INJECTION

KENALOG-10

>D>	APOTHECON	10MG/ML	N12041 001		May	CFTG
>A>	AB	10MG/ML	N12041 001		May	CFTG
	KENALOG-40					
>D>	+ APOTHECON	40MG/ML	N14901 001		May	CFTG
>A>	AB +	40MG/ML	N14901 001		May	CFTG

INJECTABLE; INJECTION

>A>		TRIAMCINOLONE ACETONIDE						
>A>	AB	SANDOZ	10MG/ML	N90166	001	May 27, 2009	May	NEWA
>A>	AB		40MG/ML	N90164	001	May 27, 2009	May	NEWA

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

SANCTURA XR

+	ALLERGAN	60MG	N22103	001	Aug 03, 2007	Apr	CAHN
+	ENDO PHARMS	60MG	N22103	001	Aug 03, 2007	Mar	CAHN

TABLET; ORAL

SANCTURA

+	ALLERGAN	20MG	N21595	001	May 28, 2004	Apr	CAHN
+	ENDO PHARMS	20MG	N21595	001	May 28, 2004	Mar	CAHN

TRYPAN BLUE

SOLUTION; OPHTHALMIC

MEMBRANEBLUE

+	DORC	0.15%	N22278	001	Feb 20, 2009	Feb	NEWA
---	------	-------	--------	-----	--------------	-----	------

URSODIOL

TABLET; ORAL

URSO 250

>D>		AXCAN	250MG	N20675	001	Dec 10, 1997	May	CFTG
>A>	AB		250MG	N20675	001	Dec 10, 1997	May	CFTG

URSO FORTE

>D>	+	AXCAN	500MG	N20675	002	Jul 21, 2004	May	CFTG
>A>	AB	+	500MG	N20675	002	Jul 21, 2004	May	CFTG

URSODIOL

>A>	AB	TEVA PHARMS	250MG	N79184	001	May 13, 2009	May	NEWA
>A>	AB		500MG	N79184	002	May 13, 2009	May	NEWA

VALRUBICIN

SOLUTION; INTRAVESICAL

VALSTAR PRESERVATIVE FREE

+	ENDO PHARM	40MG/ML	N20892	001	Sep 25, 1998	Apr	CAHN
+	ENDO PHARMS	40MG/ML	N20892	001	Sep 25, 1998	Mar	CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	+	ABRAXIS PHARM	EQ 10GM BASE/VIAL	N62663	004	Nov 28, 1997	Apr	CTEC
>D>		HOSPIRA	EQ 750MG BASE/VIAL	N62912	002	Jan 07, 2009	May	CTEC
>A>	AP		EQ 750MG BASE/VIAL	N62912	002	Jan 07, 2009	May	CTEC
>A>	AP		EQ 750MG BASE/VIAL	N62933	002	May 27, 2009	May	NEWA
AP		HOSPIRA INC	EQ 10GM BASE/VIAL	N65455	001	Apr 29, 2009	Apr	NEWA

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

@	BEDFORD	2.5MG/ML	N72888	001	Jul 28, 1995	Apr	DISC
---	---------	----------	--------	-----	--------------	-----	------

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

@	SANDOZ	40MG	N73168	001	Jul 31, 1992	Mar	DISC
@		80MG	N71423	001	May 24, 1988	Mar	DISC
@		120MG	N71424	001	May 25, 1988	Mar	DISC

ZOLPIDEM TARTRATE

TABLET; SUBLINGUAL

EDLUAR

OREXO AB	5MG	N21997 001	Mar 13, 2009	Mar	NEWA
+	10MG	N21997 002	Mar 13, 2009	Mar	NEWA

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

>D>	AB	MUTUAL PHARM	25MG	N77635 001	Dec 22, 2005	May	DISC
>A>		@	25MG	N77635 001	Dec 22, 2005	May	DISC
>D>	AB		50MG	N77635 002	Dec 22, 2005	May	DISC
>A>		@	50MG	N77635 002	Dec 22, 2005	May	DISC
>D>	AB		100MG	N77635 003	Dec 22, 2005	May	DISC
>A>		@	100MG	N77635 003	Dec 22, 2005	May	DISC

OTC DRUG PRODUCT LIST - 29TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

2-1

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

OHM LABS	650MG	N76200 001	Mar 19, 2002	Mar	CAHN
----------	-------	------------	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	5MG/5ML	N90474 002	Mar 30, 2009	Mar	NEWA
--------------------	---------	------------	--------------	-----	------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

DR REDDYS LABS LTD	5MG/5ML	N90474 001	Mar 30, 2009	Mar	NEWA
--------------------	---------	------------	--------------	-----	------

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

ORCHID HLTHCARE	5MG	N78862 001	Feb 19, 2009	Feb	NEWA
-----------------	-----	------------	--------------	-----	------

	10MG	N78862 002	Feb 19, 2009	Feb	NEWA
--	------	------------	--------------	-----	------

CETIRIZINE HYDROCHLORIDE HIVES

ORCHID HLTHCARE	5MG	N78862 003	Feb 19, 2009	Feb	NEWA
-----------------	-----	------------	--------------	-----	------

	10MG	N78862 004	Feb 19, 2009	Feb	NEWA
--	------	------------	--------------	-----	------

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

AVANTHI INC	12MG	N40829 001	May 13, 2009	Apr	NEWA
-------------	------	------------	--------------	-----	------

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM

+ RECKITT BENCKISER	EQ 30MG HBR/5ML	N18658 001	Oct 08, 1982	Feb	CAHN
---------------------	-----------------	------------	--------------	-----	------

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

BANNER PHARMACAPS	EQ 200MG FREE ACID AND POTASSIUM SALT	N78682 001	Mar 24, 2009	Mar	NEWA
-------------------	---------------------------------------	------------	--------------	-----	------

MIDOL LIQUID GELS

+ BANNER PHARMACAPS	200MG	N21472 001	Oct 18, 2002	Feb	CTNA
---------------------	-------	------------	--------------	-----	------

TABLET; ORAL

IBUPROFEN

@ SANDOZ	200MG	N70733 001	Sep 19, 1986	Mar	DISC
----------	-------	------------	--------------	-----	------

MEDIPREN

@ MCNEIL	200MG	N70475 001	Feb 06, 1986	Apr	DISC
----------	-------	------------	--------------	-----	------

@	200MG	N71215 001	Jun 26, 1986	Apr	DISC
---	-------	------------	--------------	-----	------

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50

@ LILLY	50 UNITS/ML;50 UNITS/ML	N20100 001	Apr 29, 1992	Jan	DISC
---------	-------------------------	------------	--------------	-----	------

>A> LANSOPRAZOLE

>A> CAPSULE, DELAYED REL PELLETS; ORAL

>A> PREVACID 24 HR

+ NOVARTIS	15MG	N22327 001	May 18, 2009	May	NEWA
------------	------	------------	--------------	-----	------

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

IVAX PHARMS

EQ 2MG BASE

N76880 001 Feb 18, 2009 Feb NEWA

EQ 4MG BASE

N77850 001 Feb 18, 2009 Feb NEWA

TROCHE/LOZENGE; ORAL

>A>

NICORETTE

>A>

GLAXOSMITHKLINE CONS

EQ 2MG BASE

N22360 001 May 18, 2009 May NEWA

>A>

+

EQ 4MG BASE

N22360 002 May 18, 2009 May NEWA

POTASSIUM IODIDE

SOLUTION; ORAL

THYROSHIELD

+ FLEMING

65MG/ML

N77218 001 Jan 12, 2005 Apr CRLD

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE

@ SANDOZ

EQ 75MG BASE

N75519 001 Sep 26, 2002 Mar DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 05 MAY 2009

NO MAY 2009 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2009 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
022320 001	4717720	May 31, 2010	DS DP			
	RE34440	May 31, 2010	U-818			
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
020983 001	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 06, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
<u>ALMOTRIPTAN MALATE - AXERT</u>						
021001 001	>A> 5565447	May 07, 2015	DS DP	U-969		
	>A> 5565447*PED	Nov 07, 2015				
<u>ALMOTRIPTAN MALATE - AXERT</u>						
021001 002	>A> 5565447	May 07, 2015	DS DP	U-969		
	>A> 5565447*PED	Nov 07, 2015				
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
078088 001					PC	Jul 13, 2009
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
078088 002					PC	Jul 13, 2009
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
078088 003					PC	Jul 13, 2009
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
078088 004					PC	Jul 13, 2009
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
022325 001	5134127	Jan 23, 2010	DP			
	5376645	Jan 23, 2010	DP			
	6869939	May 04, 2022	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 001	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 002	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 003	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 004	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 005	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 006	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 007	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 008	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 009	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 010	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 011	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 001	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 002	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 003	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 004	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 005	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMMONIA, N-13 - AMMONIA N 13</u>						
022119 001					NCE W	Aug 23, 2012 Aug 23, 2012
<u>AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE - PREVPAC</u>						
050757 001	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	5013743	Feb 12, 2010	U-452			
	5013743*PED	Aug 12, 2010				
	5045321	Sep 03, 2008	DP			
	5045321*PED	Mar 03, 2009				
	5093132	Sep 03, 2008	DP			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP			
	5433959*PED	Mar 03, 2009				
<u>ANASTROZOLE - ARIMIDEX</u>						
020541 001	RE36617	Dec 27, 2009	DS DP U-946			
<u>ANIDULAFUNGIN - ERAXIS</u>						
021632 001	>A> 5965525	Feb 17, 2020	DS DP U-540			
<u>ANIDULAFUNGIN - ERAXIS</u>						
021632 002	>A> 5965525	Feb 17, 2020	DS DP U-540			
<u>ARMODAFINIL - NUVIGIL</u>						
021875 002					NP	Jun 15, 2010
<u>ARMODAFINIL - NUVIGIL</u>						
021875 005					NP	Jun 15, 2010
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
021248 001	>A> 6982096	Nov 10, 2018	U-651			
<u>ARTEMETHER; LUMEFANTRINE - COARTEM</u>						
022268 001					NCE	Apr 07, 2014
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 001	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 002	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 003	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 004	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AZITHROMYCIN - AZASITE</u>						
050810 001	5192535	Mar 09, 2010	DP U-709			
	6239113	Mar 31, 2019	U-709			
	6569443	Mar 31, 2019	DP U-709			
	6861411	Nov 25, 2018	U-709			
	7056893	Mar 31, 2019	DP U-709			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
022249 002					>A> I-580	Oct 31, 2011
					>A> NCE	Mar 20, 2013
					>A> ODE	Mar 20, 2015
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
050819 001	5733886	Mar 31, 2015	DP U-124			
	6117843	Feb 18, 2012	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - DUAC</u>						
050741 001	5466446	Feb 16, 2014	DS DP			
<u>BENZYL ALCOHOL - ULESFIA</u>						
022129 001	>A> 5858383	Aug 11, 2017	U-970		NCE	Apr 09, 2014
	>A> 6139849	Aug 11, 2017	U-970			
	>A> 6793931	Jul 11, 2022	DP U-970			
	>A> 7294342	Jul 11, 2022	U-970			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
022308 001					>A> NCE	May 28, 2014
<u>BETAMETHASONE VALERATE - LUXIQ</u>						
020934 001	7078058	May 24, 2017	DP			
<u>BIMATOPROST - LATISSE</u>						
022369 001					NP	Dec 24, 2011
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA</u>						
050786 001	5196205	Mar 23, 2010	U-933			
	5476669	Mar 23, 2010	U-933			
	6350468	Dec 14, 2018	U-956			
	6350468	Dec 14, 2018	U-932			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
020866 001					>A> NP	May 05, 2012
<u>BUDESONIDE - PULMICORT RESPULES</u>						
020929 001	7524834	Nov 11, 2018	DP U-966			
	7524834*PED	May 11, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - PULMICORT RESPULES</u>						
020929 002	7524834	Nov 11, 2018	DP U-966			
	7524834*PED	May 11, 2019				
<u>BUDESONIDE - PULMICORT RESPULES</u>						
020929 003	7524834	Nov 11, 2018	DP U-966			
	7524834*PED	May 11, 2019				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
021929 001					I-582	Feb 27, 2012
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
021929 002					I-582	Feb 27, 2012
<u>CALCITRIOL - VECTICAL</u>						
022087 001					NDF	Jan 23, 2012
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPICID COMPLETE</u>						
020958 001	5075114	May 23, 2010	DP			
	5075114*PED	Nov 23, 2010				
	6814978	Aug 26, 2021	DP			
	6814978*PED	Feb 26, 2022				
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>						
021823 001	5583122	Dec 10, 2013	DS DP U-353			
	5583122*PED	Jun 10, 2014				
	5994329	Jul 17, 2018	U-353			
	5994329*PED	Jan 17, 2019				
	6015801	Jul 17, 2018	U-353			
	6015801*PED	Jan 17, 2019				
	6096342	Nov 21, 2011	DP			
	6096342*PED	May 21, 2012				
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
	6432932	Jul 17, 2018	U-595			
	6432932*PED	Jan 17, 2019				
	6465443	Aug 14, 2018	DP			
	6465443*PED	Feb 14, 2019				
<u>CICLESONIDE - ALVESCO</u>						
021658 002					NDF	Jan 10, 2011
					NCE	Oct 20, 2011
<u>CICLESONIDE - ALVESCO</u>						
021658 003					NDF	Jan 10, 2011
					NCE	Oct 20, 2011
<u>CIPROFLOXACIN HYDROCHLORIDE - CETRAXAL</u>						
021918 001					>A> NDF	May 01, 2012
<u>CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE - CIPRO HC</u>						
020805 001	>A> 5843930	Jun 06, 2015	U-646			
<u>CLARITHROMYCIN - BIAXIN XL</u>						
050775 001	6551616	Jul 15, 2017	U-924			
<u>CLOBETASOL PROPIONATE - OLUX</u>						
021142 001	6126920	Mar 01, 2016	U-484			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
020839 002	4847265	Nov 17, 2011	DS DP			
	6429210	Jun 10, 2019	DS DP			
	6504030	Jun 10, 2019	DS			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
021141 001	5607669	Jun 10, 2014	U-323			
	5607669*PED	Dec 10, 2014				
	5679717	Apr 29, 2014	U-323			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014				
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	U-323			
	5917007*PED	Oct 29, 2014				
	5919832	Jun 10, 2014				
	5919832*PED	Dec 10, 2014				
	6066678	Jun 10, 2014	U-323			
	6066678*PED	Dec 10, 2014				
	6433026	Jun 10, 2014				
	6433026*PED	Dec 10, 2014				
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
021176 001	5607669	Jun 10, 2014	U-323		I-553	Jan 18, 2011
	5607669*PED	Dec 10, 2014			PED	Jul 18, 2011
	5679717	Apr 29, 2014	U-323			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS U-323			
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS U-323			
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP U-757			
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022	U-851			
	7229613*PED	Oct 17, 2022				
<u>CYCLOSPORINE - SANDIMMUNE</u>						
050625 001	7511014	Feb 16, 2010	DP			
<u>CYCLOSPORINE - SANDIMMUNE</u>						
050625 002	7511014	Feb 16, 2010	DP			
<u>CYCLOSPORINE - SANDIMMUNE</u>						
050625 003	7511014	Feb 16, 2010	DP			
<u>DASATINIB - SPRYCEL</u>						
021986 001	7491725	Oct 13, 2025	DS DP		>A> D-120	May 21, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
021986 002	7491725	Oct 13, 2025	DS DP		>A> D-120	May 21, 2012
<u>DASATINIB - SPRYCEL</u>						
021986 003	7491725	Oct 13, 2025	DS DP		>A> D-120	May 21, 2012
<u>DASATINIB - SPRYCEL</u>						
021986 004	7491725	Oct 13, 2025	DS DP		>A> D-120	May 21, 2012
<u>DEGARELIX ACETATE - DEGARELIX ACETATE</u>						
022201 001	5925730	Apr 11, 2017	DS DP U-943			
<u>DEGARELIX ACETATE - DEGARELIX ACETATE</u>						
022201 002	5925730	Apr 11, 2017	DS DP U-943			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
050818 001	5149694	Sep 22, 2009		U-953		
<u>DEXLANSOPRAZOLE - KAPIDEX</u>						
022287 001	5045321	Sep 03, 2008	DP		NP	Jan 30, 2012
	5045321*PED	Mar 03, 2009			PED	Jul 30, 2012
	5093132	Sep 03, 2008	DP U-949			
	5093132	Sep 03, 2008	DP U-950			
	5093132	Sep 03, 2008	DP U-951			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP U-949			
	5433959	Sep 03, 2008	DP U-950			
	5433959	Sep 03, 2008	DP U-951			
	5433959*PED	Mar 03, 2009				
	6462058	Jun 15, 2020	DS DP U-951			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-949			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - KAPIDEX</u>						
022287 002	5045321	Sep 03, 2008	DP		NP	Jan 30, 2012
	5045321*PED	Mar 03, 2009			PED	Jul 30, 2012
	5093132	Sep 03, 2008	DP U-949			
	5093132	Sep 03, 2008	DP U-950			
	5093132	Sep 03, 2008	DP U-951			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP U-949			
	5433959	Sep 03, 2008	DP U-950			
	5433959	Sep 03, 2008	DP U-951			
	5433959*PED	Mar 03, 2009				
	6462058	Jun 15, 2020	DS DP U-951			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-949			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
020062 005	5286497	May 20, 2011	DP			
	5439689	Aug 08, 2012	DP U-107			
	5470584	May 20, 2011	DP			
<u>DINOPROSTONE - CERVIDIL</u>						
020411 001	5269321	Jul 14, 2012	DP U-110			
<u>DIVALPROEX SODIUM - DIVALPROEX SODIUM</u>						
077567 002					PC	Aug 01, 2009
<u>DOXERCALCIFEROL - HECTOROL</u>						
021027 001	5707980	Aug 17, 2010	U-321	Y		
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
022291 001	7473686	Jul 24, 2021	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
022291 002	7473686	Jul 24, 2021	DS DP U-930			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021323 001					NPP	Mar 19, 2012
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021323 002					NPP	Mar 19, 2012
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021323 003					NPP	Mar 19, 2012
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021365 001					NPP	Mar 19, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021153 001					NPP PED	Apr 28, 2009 Oct 28, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021153 002					NPP PED	Apr 28, 2009 Oct 28, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021957 001					NPP PED	Apr 28, 2009 Oct 28, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021957 002					NPP PED	Apr 28, 2009 Oct 28, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
022101 001					NPP PED	Feb 27, 2011 Aug 27, 2011
<u>ESTRADIOL - ELESTRIN</u>						
021813 001	7470433	Aug 03, 2021	DP			
<u>EVEROLIMUS - AFINITOR</u>						
022334 001	5665772	Sep 09, 2014	DS DP		NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP			
	7297703	Dec 06, 2019	DP			
<u>EVEROLIMUS - AFINITOR</u>						
022334 002	5665772	Sep 09, 2014	DS DP		NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP			
	7297703	Dec 06, 2019	DP			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
021773 001	>A> 7521423	Oct 15, 2017	DP			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
021773 002	>A> 7521423	Oct 15, 2017	DP			
<u>FEBUXOSTAT - ULORIC</u>						
021856 001	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
<u>FEBUXOSTAT - ULORIC</u>						
021856 002	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
<u>FLUDARABINE PHOSPHATE - FLUDARABINE PHOSPHATE</u>						
022273 001	7148207	Dec 20, 2022	DP U-944		NDF	Dec 18, 2011
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
018936 001	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
018936 003	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
018936 006	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 001	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 002	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 003	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 004	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 005	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 100</u>						
020833 002	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 250</u>						
020833 003	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 50</u>						
020833 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
021433 001	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Jun 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
021433 002	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
021433 003	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015	U-710			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015	U-582			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015	U-583			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021	U-581			
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
021077 001	5590645	Mar 01, 2011	DP		M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
021077 002	5590645	Mar 01, 2011	DP		M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
021077 003	5590645	Mar 01, 2011	DP		M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
021254 001	5658549	Aug 19, 2014	DP		U-738	
	5658549*PED	Feb 19, 2015			U-738	
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP		U-738	
	6253762*PED	Oct 14, 2015			U-738	
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6341168	Jun 08, 2018	DP			
	6341168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017				
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021			U-841	
	6743413*PED	Dec 01, 2021			U-841	
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
021254 002	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6341168	Jun 08, 2018	DP			
	6341168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-841			
	6743413*PED	Dec 01, 2021	U-841			
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
021254 003	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6341168	Jun 08, 2018	DP			
	6341168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-841			
	6743413*PED	Dec 01, 2021	U-841			
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
021519 001					M-83	Apr 14, 2011
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
021519 002					M-83	Apr 14, 2011
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
021519 003					M-83	Apr 14, 2011
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
022244 001	6204257	Jun 07, 2018	DS DP U-945		NCE	Dec 12, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADODIAMIDE - OMNISCAN</u>						
022066 002	5362475	Nov 08, 2011	DS			
<u>GATIFLOXACIN - ZYMAR</u>						
021493 001	>A> 4980470	Dec 15, 2009	DS DP			
	>A> 4980470*PED	Jun 15, 2010				
	>A> 5880283	Dec 05, 2015				
	>A> 5880283*PED	Jun 05, 2016				
	>A> 6333045	Aug 20, 2019	DP			
	>A> 6333045*PED	Feb 20, 2020				
<u>GLATIRAMER ACETATE - COPAXONE</u>						
020622 001					I-594	Feb 27, 2012
<u>GLATIRAMER ACETATE - COPAXONE</u>						
020622 002					I-594	Feb 27, 2012
<u>GOSERELIN ACETATE - ZOLADEX</u>						
019726 001	7500964	Feb 26, 2021	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
020578 001	7500964	Feb 26, 2021	DP			
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
021162 003	5591762	Jan 07, 2014	DS DP U-3			
<u>ILOPERIDONE - FANAPT</u>						
022192 001	>A> RE39198	Nov 15, 2011	DS DP U-971		>A> NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 002	>A> RE39198	Nov 15, 2011	DS DP U-971		>A> NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 003	>A> RE39198	Nov 15, 2011	DS DP U-971		>A> NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 004	>A> RE39198	Nov 15, 2011	DS DP U-971		>A> NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 005	>A> RE39198	Nov 15, 2011	DS DP U-971		>A> NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 006	>A> RE39198	Nov 15, 2011	DS DP U-971		>A> NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 007	>A> RE39198	Nov 15, 2011	DS DP U-971		>A> NCE	May 06, 2014
<u>IMATINIB MESYLATE - GLEEVEC</u>						
021588 001					I-583	Dec 19, 2011
<u>IMATINIB MESYLATE - GLEEVEC</u>						
021588 002					I-583	Dec 19, 2011
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
021536 001	5750497	May 16, 2019	DS DP U-668			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
021081 001	5656722	Aug 12, 2014	DS DP U-948			
	5656722*PED	Feb 12, 2015				
	7476652	Jul 23, 2023	DP			
	7476652*PED	Jan 23, 2024				
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
021629 002					NCE	Apr 16, 2009
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
021629 003					NPP NCE	Oct 24, 2011 Apr 16, 2009
<u>IODIXANOL - VISIPAQUE 270</u>						
020351 001	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 270</u>						
020808 001	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
020351 002	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
020808 002	RE36418	Jul 12, 2011	DP			
<u>IXABEPILONE - IXEMPRA KIT</u>						
022065 001	6605599	May 26, 2018	DS DP U-961			
	6670384	Jan 23, 2022	DP U-960			
	6670384	Jan 23, 2022	DP U-959			
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			
<u>IXABEPILONE - IXEMPRA KIT</u>						
022065 002	6605599	May 26, 2018	DS DP U-961			
	6670384	Jan 23, 2022	DP U-960			
	6670384	Jan 23, 2022	DP U-959			
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			
<u>LANSOPRAZOLE - PREVACID</u>						
020406 001					M-85 PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
020406 002					M-85 PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
021281 001					M-85 PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
021281 002					M-85 PED	Oct 28, 2011 Apr 28, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LANSOPRAZOLE - PREVACID</u>						
021428 001	7431942	May 17, 2019	DP		M-85	Oct 28, 2011
	7431942*PED	Nov 17, 2019			PED	Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
021428 002	7431942	May 17, 2019	DP		M-85	Oct 28, 2011
	7431942*PED	Nov 17, 2019			PED	Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID 24 HR</u>						
022327 001					>A> NP	May 18, 2012
<u>LANSOPRAZOLE - PREVACID IV</u>						
021566 001	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	7396841	Aug 17, 2021	DP U-947			
	7396841*PED	Feb 17, 2022				
<u>LANSOPRAZOLE; NAPROXEN - PREVACID NAPRAPAC 500 (COPACKAGED)</u>						
021507 004	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	5045321	Sep 03, 2008	DP			
	5045321*PED	Mar 03, 2009				
	5093132	Sep 03, 2008	DP			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP			
	5433959*PED	Mar 03, 2009				
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 001	5968976	Oct 26, 2018	DP U-613			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 002	5968976	Oct 26, 2018	DP U-613			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 003	5968976	Oct 26, 2018	DP U-613			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 004	5968976	Oct 26, 2018	DP U-613			
<u>LEVETIRACETAM - KEPPRA XR</u>						
022285 002					NDF	Sep 12, 2011
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
022114 001					NPP	Jan 08, 2012
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
021487 001	5061703	Apr 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
021487 002	5061703	Apr 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
021627 001	5061703	Apr 11, 2015	U-539			
<u>MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK</u>						
021308 001	>A> 5514698	Mar 21, 2014		Y		
	>A> 6153635	Nov 28, 2020		Y		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 001	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 002	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 003	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 004	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
021067 002	5394868	Jun 25, 2012	DP		NPP	Feb 01, 2011
	5394868*PED	Dec 25, 2012				
	5687710	Nov 18, 2014	DP			
	5687710*PED	May 18, 2015				
	5829434	Nov 03, 2015	DP			
	5829434*PED	May 03, 2016				
	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6240918	Feb 20, 2017	DP			
	6240918*PED	Aug 20, 2017				
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
	6503537	Mar 17, 2018	DP			
	6503537*PED	Sep 17, 2018				
	6677322	Jan 27, 2014	U-645			
	6677322*PED	Jul 27, 2014				
	6949532	Jan 27, 2014	U-645			
	6949532*PED	Jul 27, 2014				
<u>MORPHINE SULFATE - AVINZA</u>						
021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
021260 006	6066339	Nov 25, 2017	DP			
<u>NITROGLYCERIN - NITROMIST</u>						
021780 001	5869082	Apr 16, 2016	DP			
<u>OLANZAPINE - ZYPREXA</u>						
020592 001	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 002	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 003	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE - ZYPREXA</u>						
020592 004	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 005	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 006	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 001	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 002	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 003	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 004	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
<u>OMEGA-3-ACID ETHYL ESTERS - LOVAZA</u>						
021654 001	5656667	Apr 10, 2017	DS DP U-822			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
022204 001	7029694	Apr 26, 2020	DP U-318		NDF	Jan 27, 2012
	7179483	Apr 26, 2020	U-318			
<u>PALIPERIDONE - INVEGA</u>						
021999 006	5158952	Oct 27, 2009	DP U-90			
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
020987 001	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	5997903	Dec 07, 2016				
	5997903*PED	Jun 07, 2017				
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
020987 002	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	5997903	Dec 07, 2016				
	5997903*PED	Jun 07, 2017				
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
022020 001	4758579	Jul 19, 2010	DS DP U-859			
	4758579*PED	Jan 19, 2011				
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
020988 001	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	6780881	Nov 17, 2021	DP			
	6780881*PED	May 17, 2022				
	7351723	Nov 17, 2021	DP			
	7351723*PED	May 17, 2022				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
022159 001	6764678	May 11, 2021	U-967			
	6872390	May 11, 2021	DP			
	7229630	Jun 20, 2023	DP			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
021332 002	5814600	Sep 29, 2015	U-639			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-637			
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017	U-640			
	6114304	Sep 05, 2017	U-637			
	6608029	Sep 07, 2013	U-641			
	6608029	Sep 07, 2013	U-640			
	6608029	Sep 07, 2013	U-637			
	6610824	Mar 03, 2011	DS			
	7407934	Mar 08, 2011	U-640			
	7407934	Mar 08, 2011	U-637			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
021332 003	5814600	Sep 29, 2015	U-639			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-637			
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017	U-640			
	6114304	Sep 05, 2017	U-637			
	6608029	Sep 07, 2013	U-641			
	6608029	Sep 07, 2013	U-640			
	6608029	Sep 07, 2013	U-637			
	6610824	Mar 03, 2011	DS			
	7407934	Mar 08, 2011	U-640			
	7407934	Mar 08, 2011	U-637			
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 001	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 002	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 003	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 004	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
<u>QUETIAPINE FUMARATE - SEROQUEL</u>									
020639 005	4879288	Sep	26, 2011	DS	DP	U-550	I-560	May	13, 2011
	4879288*PED	Mar	26, 2012				I-503	Oct	20, 2009
							PED	Nov	13, 2011
							PED	Apr	20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>									
020639 006	4879288	Sep	26, 2011	DS	DP	U-550	I-560	May	13, 2011
	4879288*PED	Mar	26, 2012				I-503	Oct	20, 2009
							PED	Nov	13, 2011
							PED	Apr	20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>									
020639 007	4879288	Sep	26, 2011	DS	DP	U-550	I-560	May	13, 2011
	4879288*PED	Mar	26, 2012				I-503	Oct	20, 2009
							PED	Nov	13, 2011
							PED	Apr	20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>									
022047 001	4879288	Sep	26, 2011	DS	DP	U-814	D-117	Oct	08, 2011
	4879288	Sep	26, 2011				I-576	Oct	08, 2011
	4879288*PED	Mar	26, 2012	DS	DP	U-601	I-575	Oct	08, 2011
							I-574	Oct	08, 2011
	5948437	May	28, 2017	DP	U-814	NDF	May	17, 2010	
	5948437	May	28, 2017			DP	U-601	PED	Apr
	5948437*PED	Nov	28, 2017			PED	Nov	17, 2010	
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>									
022047 002	4879288	Sep	26, 2011	DS	DP	U-814	D-117	Oct	08, 2011
	4879288	Sep	26, 2011				I-576	Oct	08, 2011
	4879288*PED	Mar	26, 2012	DS	DP	U-601	I-575	Oct	08, 2011
							I-574	Oct	08, 2011
	5948437	May	28, 2017	DP	U-814	NDF	May	17, 2010	
	5948437	May	28, 2017			DP	U-601	PED	Apr
	5948437*PED	Nov	28, 2017			PED	Nov	17, 2010	
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>									
022047 003	4879288	Sep	26, 2011	DS	DP	U-814	D-117	Oct	08, 2011
	4879288	Sep	26, 2011				I-576	Oct	08, 2011
	4879288*PED	Mar	26, 2012	DS	DP	U-601	I-575	Oct	08, 2011
							I-574	Oct	08, 2011
	5948437	May	28, 2017	DP	U-814	NDF	May	17, 2010	
	5948437	May	28, 2017			DP	U-601	PED	Apr
	5948437*PED	Nov	28, 2017			PED	Nov	17, 2010	
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>									
022047 004	4879288	Sep	26, 2011	DS	DP	U-814	D-117	Oct	08, 2011
	4879288	Sep	26, 2011				I-576	Oct	08, 2011
	4879288*PED	Mar	26, 2012	DS	DP	U-601	I-575	Oct	08, 2011
							I-574	Oct	08, 2011
	5948437	May	28, 2017	DP	U-814	NDF	May	17, 2010	
	5948437	May	28, 2017			DP	U-601	PED	Apr
	5948437*PED	Nov	28, 2017			PED	Nov	17, 2010	
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>									
022047 005	4879288	Sep	26, 2011	DS	DP	U-814	D-117	Oct	08, 2011
	4879288	Sep	26, 2011				I-576	Oct	08, 2011
	4879288*PED	Mar	26, 2012	DS	DP	U-601	I-575	Oct	08, 2011
							I-574	Oct	08, 2011
	5948437	May	28, 2017	DP	U-814	NDF	May	17, 2010	
	5948437	May	28, 2017			DP	U-601	PED	Apr
	5948437*PED	Nov	28, 2017			PED	Nov	17, 2010	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RASAGILINE MESYLATE - AZILECT</u>						
021641 001	>A> 5453446	Feb 07, 2017	U-219			
<u>RASAGILINE MESYLATE - AZILECT</u>						
021641 002	>A> 5453446	Feb 07, 2017	U-219			
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
020630 001	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
020630 002	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
020630 003	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
<u>REPAGLINIDE - PRANDIN</u>						
020741 001	6677358	Jun 12, 2018	DS DP U-968			
<u>REPAGLINIDE - PRANDIN</u>						
020741 002	6677358	Jun 12, 2018	DS DP U-968			
<u>REPAGLINIDE - PRANDIN</u>						
020741 003	6677358	Jun 12, 2018	DS DP U-968			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 001	5583122	Dec 10, 2013	U-222			
	5583122*PED	Jun 10, 2014				
	6096342	Nov 22, 2011				
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018				
	6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 002	5583122	Dec 10, 2013	U-222			
	5583122*PED	Jun 10, 2014				
	6096342	Nov 22, 2011				
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018				
	6165513*PED	Dec 10, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 003	5583122	Dec 10, 2013	DS DP U-756		I-309	Aug 11, 2009
	5583122	Dec 10, 2013	DS DP U-222		PED	Feb 11, 2010
	5583122*PED	Jun 10, 2014				
	5994329	Jul 17, 2018	U-353			
	5994329*PED	Jan 17, 2019				
	6015801	Jul 17, 2018	U-353			
	6015801*PED	Jan 17, 2019				
	6096342	Nov 22, 2011	DP			
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
	6432932	Jul 17, 2018	U-595			
	6432932*PED	Jan 17, 2019				
	6465443	Aug 14, 2018	DP			
	6465443*PED	Feb 14, 2019				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 004	5583122	Dec 10, 2013	DS DP U-353		D-105	Apr 16, 2010
	5583122*PED	Jun 10, 2014			PED	Oct 16, 2010
	6096342	Nov 22, 2011	DP U-353			
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 005	5583122	Dec 10, 2013	DS DP U-353		NS	Apr 22, 2011
	5583122*PED	Jun 10, 2014			PED	Oct 22, 2011
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
	7192938	May 06, 2023	U-353			
	7192938*PED	Nov 06, 2023				
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
021346 001					>A> I-597	May 15, 2012
					>A> I-596	May 15, 2012
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
021346 002					>A> I-597	May 15, 2012
					>A> I-596	May 15, 2012
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
021346 003					>A> I-597	May 15, 2012
					>A> I-596	May 15, 2012
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
021346 004					>A> I-597	May 15, 2012
					>A> I-596	May 15, 2012
<u>RISPERIDONE - RISPERIDONE</u>						
076440 001					PC	Jul 29, 2009
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
022008 006	5422123	Jun 06, 2012	DP		NDF	Jun 13, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SALMETEROL XINAFOATE - SEREVENT</u>						
020692 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>SILDENAFIL CITRATE - REVATIO</u>						
021845 001					>A> I-598	May 07, 2009
<u>SILODOSIN - RAPAFLO</u>						
022206 001	5780485	Nov 13, 2012	U-902			
<u>SILODOSIN - RAPAFLO</u>						
022206 002	5780485	Nov 13, 2012	U-902			
<u>SINECATECHINS - VEREGEN</u>						
021902 001	5795911	Oct 31, 2020	U-172			
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 001					I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 004	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 005	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 006	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 007	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 004	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 005	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 006	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 007	5849700	Dec 15, 2015	U-340		I-572	Oct 31, 2011
	5849704	Dec 15, 2015	DP U-340		I-551	Sep 20, 2010
					I-536	May 31, 2010
					ODE	May 31, 2014
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076572 001					PC	Aug 08, 2009
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076840 001					PC	Aug 08, 2009
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076840 002					PC	Aug 08, 2009
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076840 003					PC	Aug 08, 2009
<u>SUNITINIB MALATE - SUTENT</u>						
021938 004	6573293	Feb 15, 2021	DS DP U-703		NCE	Jan 26, 2011
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>TADALAFIL - ADCIRCA</u>						
022332 001					>A> NP	May 22, 2012
<u>TELIVUDINE - TYZEKA</u>						
022154 001					NCE	Oct 25, 2011
<u>TEMOZOLOMIDE - TEMODAR</u>						
022277 001	5260291	Aug 11, 2013	DS DP U-619			
	5260291*PED	Feb 11, 2014				
	6987108	Sep 08, 2023	DP			
<u>TIGECYCLINE - TYGACIL</u>						
021821 001					I-588	Mar 20, 2012
					I-587	Mar 20, 2012
					I-586	Mar 20, 2012
<u>TOLVAPTAN - SAMSCA</u>						
022275 001					>A> NCE	May 19, 2014
<u>TOLVAPTAN - SAMSCA</u>						
022275 002					>A> NCE	May 19, 2014
<u>TOLVAPTAN - SAMSCA</u>						
022275 003					>A> NCE	May 19, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
020505 001	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 002	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 003	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TOPAMAX</u>						
020505 004	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 005	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 006	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020844 001	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020844 002	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
020844 003	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPIRAMATE</u>						
076448 001					PC	Oct 12, 2009
<u>TOPIRAMATE - TOPIRAMATE</u>						
076448 002					PC	Oct 12, 2009
<u>TOPIRAMATE - TOPIRAMATE</u>						
077868 001					PC	Oct 12, 2009
<u>TOPIRAMATE - TOPIRAMATE</u>						
077868 002					PC	Oct 12, 2009
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
021745 001					NP	Dec 30, 2011
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
021745 002					NP	Dec 30, 2011
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
021745 003					NP	Dec 30, 2011
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
022278 001					NCE ODE	Dec 16, 2009 Dec 16, 2011
<u>ZOLEDRONIC ACID - RECLAST</u>						
021817 001					>A> I-595 I-584 I-581	May 29, 2012 Mar 15, 2012 Dec 19, 2011
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
021997 001	6761910	Sep 24, 2018	DP U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
021997 002	6761910	Sep 24, 2018	DP U-674			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
-----------------	-----------	------------------------------	-----------------	-------------------------------	---------------------------	-----------------------------------

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 29th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>